[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 23843
1. Nowak M, Madej JA, Dziegiel P: Correlation between MCM-3 protein expression and grade of malignancy in mammary adenocarcinomas and soft tissue fibrosarcomas in dogs. In Vivo; 2009 Jan-Feb;23(1):49-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between MCM-3 protein expression and grade of malignancy in mammary adenocarcinomas and soft tissue fibrosarcomas in dogs.
  • Localization of MCM-3 and the extent of its expression were evaluated in mammary adenocarcinomas and soft tissue fibrosarcomas in dogs.
  • MATERIALS AND METHODS: The research material was sampled in the course of surgery in 71 dogs of various breeds, aged 4 to 14 years (50 cases of mammary adenocarcinoma and 21 cases of soft tissue fibrosarcoma).
  • RESULTS: Nuclear expression of MCM-3 was detected in 70% adenocarcinomas and in over 71% of fibrosarcomas.
  • Statistical analysis demonstrated strong positive correlation (r=0.71 for fibrosarcomas, r=0.52 for adenocarcinomas; p<0.05) between MCM-3 expression and grade of malignancy in the studied tumours.
  • [MeSH-major] Adenocarcinoma / pathology. Fibrosarcoma / pathology. Mammary Neoplasms, Animal / pathology. Nuclear Proteins / metabolism. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19368124.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins
  •  go-up   go-down


2. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A: Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer; 2009 Feb 10;100(3):551-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis.
  • Use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of gastric or oesophageal adenocarcinomas.
  • We examined the association between self-reported use of aspirin or non-aspirin NSAIDs in the earlier 12 months and gastric non-cardia (N=182), gastric cardia (N=178), and oesophageal adenocarcinomas (N=228) in a prospective cohort (N=311 115) followed for 7 years.
  • Use of any aspirin (HR, 95% CI: 0.64, 0.47-0.86) or other NSAIDs (0.68, 0.51-0.92) was associated with a significantly lower risk of gastric non-cardia adenocarcinoma.
  • We found no significant association between using aspirin (1.00, 0.73-1.37) or other NSAIDs (0.90, 69-1.17) and oesophageal adenocarcinoma.
  • We also performed a meta-analysis of the association between the use of NSAIDs and risk of gastric and oesophageal adenocarcinoma.
  • In this analysis, aspirin use was inversely associated with both gastric and oesophageal adenocarcinomas, with summary odds ratios (95% CI) for non-cardia, cardia, and oesophageal adenocarcinomas of 0.64 (0.52-0.80), 0.82 (0.65-1.04), and 0.64 (0.52-0.79), respectively.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2006 May 1;66(9):4975-82 [16651456.001]
  • [Cites] Int J Cancer. 2006 Jul 1;119(1):202-7 [16450404.001]
  • [Cites] Digestion. 2006;74(2):109-15 [17167266.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Ann Intern Med. 2007 Mar 6;146(5):361-4 [17339621.001]
  • [Cites] Ann Intern Med. 2007 Mar 6;146(5):365-75 [17339622.001]
  • [Cites] J Natl Cancer Inst. 2007 Apr 4;99(7):545-57 [17405999.001]
  • [Cites] Am J Epidemiol. 2007 Jun 15;165(12):1424-33 [17420181.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Oct;5(10):1154-1159.e3 [17644046.001]
  • [Cites] Expert Rev Cardiovasc Ther. 2008 Jan;6(1):95-107 [18095910.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):126-34 [18187391.001]
  • [Cites] Eur J Cancer. 2008 Feb;44(3):465-71 [18221867.001]
  • [Cites] Gut. 2008 May;57(5):561-7 [18194986.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1169-78 [18483339.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2008 Jun;5(6):321-31 [18446147.001]
  • [Cites] Lancet. 2008 Aug 2;372(9636):350-2 [18675670.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Oct;1(5):329-38 [19138977.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):119-23 [10667472.001]
  • [Cites] BMJ. 2000 Jun 17;320(7250):1642-6 [10856067.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • [Cites] Eur J Cancer Prev. 2000 Jun;9(3):185-91 [10954258.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):965-8 [11286478.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1119-25 [11744517.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2096-102 [12412162.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):672-4 [12618872.001]
  • [Cites] Br J Cancer. 2003 Jun 2;88(11):1687-92 [12771981.001]
  • [Cites] Prog Exp Tumor Res. 2003;37:1-24 [12795046.001]
  • [Cites] J Natl Cancer Inst. 2003 Dec 3;95(23):1784-91 [14652240.001]
  • [Cites] BMC Cancer. 2003 Oct 31;3:28 [14588079.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):885-7; author reply 887 [15173278.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Sep 15;20(6):645-55 [15352913.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5B):3177-84 [15510608.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1322-7 [8443812.001]
  • [Cites] Epidemiology. 1994 Mar;5(2):138-46 [8172988.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1116-9 [8630885.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):295-9 [8903469.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):473-6 [10404057.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):444-50 [15734971.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4766-72 [16899628.001]
  • (PMID = 19156150.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  • [Other-IDs] NLM/ PMC2658549
  •  go-up   go-down


3. Nowak M, Madej JA, Podhorska-Okolow M, Dziegiel P: Expression of extracellular matrix metalloproteinase (MMP-9), E-cadherin and proliferation-associated antigen Ki-67 and their reciprocal correlation in canine mammary adenocarcinomas. In Vivo; 2008 Jul-Aug;22(4):463-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of extracellular matrix metalloproteinase (MMP-9), E-cadherin and proliferation-associated antigen Ki-67 and their reciprocal correlation in canine mammary adenocarcinomas.
  • BACKGROUND: The purpose of the present study was to determine the expression of the proteins related to tumour metastatic potential, including matrix metalloproteinase (MMP)-9 and E-cadherin, in correlation with the expression of proliferation-associated antigen (Ki-67) in canine mammary adenocarcinomas.
  • CONCLUSION: The positive correlation (r=0.375) between expressions of MMP-9 and Ki-67 and negative correlations between E-cadherin and Ki-67 (r=-0.383) as well as between MMP-9 and E-cadherin (r=-0.45) could suggest that expression and biological significance of the studied markers in mammary adenocarcinomas in dogs resembles the pattern noted in ductal carcinoma, i.e. in the most frequent histological type of malignant tumour in humans.
  • This may point to suitability of the animal model in studies on mechanism of neoplasia and metastases in humans.
  • [MeSH-major] Adenocarcinoma / metabolism. Cadherins / biosynthesis. Gene Expression Regulation, Neoplastic. Ki-67 Antigen / biosynthesis. Mammary Neoplasms, Animal / metabolism. Matrix Metalloproteinase 9 / biosynthesis
  • [MeSH-minor] Animals. Cell Proliferation. Dog Diseases / metabolism. Dogs. Gene Expression Profiling. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18712173.001).
  • [ISSN] 0258-851X
  • [Journal-full-title] In vivo (Athens, Greece)
  • [ISO-abbreviation] In Vivo
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cadherins; 0 / Ki-67 Antigen; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


Advertisement
4. Partheen K, Levan K, Osterberg L, Claesson I, Sundfeldt K, Horvath G: External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas. BMC Cancer; 2009;9:336
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomas.
  • METHODS: We analysed the gene expression of CLU, ITGB3, CAPG, and PRAME in 30 advanced staged serous adenocarcinomas with quantitative real-time polymerase chain reaction (QPCR) and the protein levels were analysed in 98 serous adenocarcinomas with western blot for semiquantitative analysis.
  • [MeSH-major] Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Integrin beta3 / genetics. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Microfilament Proteins / genetics. Microfilament Proteins / metabolism. Middle Aged. Neoplasm Staging. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Jan 1;60(1):28-34 [10646846.001]
  • [Cites] Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1215-33 [18217975.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Feb;127(2):73-9 [11216917.001]
  • [Cites] Cell Tissue Res. 2001 Sep;305(3):285-98 [11572082.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):186-94 [11774263.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Clin Exp Metastasis. 2002;19(5):427-36 [12198771.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9482-7 [12874388.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2298-304 [14755245.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4307-13 [15240516.001]
  • [Cites] J Clin Invest. 1982 Feb;69(2):263-9 [6460044.001]
  • [Cites] J Clin Invest. 1985 Mar;75(3):896-901 [3156882.001]
  • [Cites] Cell. 1986 Jul 18;46(2):271-82 [3487386.001]
  • [Cites] Bioessays. 1987 Oct;7(4):176-9 [2825660.001]
  • [Cites] Mol Biol Cell. 1993 Sep;4(9):953-61 [8257797.001]
  • [Cites] J Cell Biol. 1994 Feb;124(4):619-26 [8106557.001]
  • [Cites] Gynecol Oncol. 1996 Aug;62(2):260-7 [8751559.001]
  • [Cites] Immunity. 1997 Feb;6(2):199-208 [9047241.001]
  • [Cites] Hum Pathol. 1997 Apr;28(4):443-9 [9104944.001]
  • [Cites] Biochem J. 1997 Nov 15;328 ( Pt 1):45-50 [9359832.001]
  • [Cites] Biochim Biophys Acta. 1998 Dec 10;1448(2):290-7 [9920419.001]
  • [Cites] J Biol Chem. 1999 Mar 12;274(11):6875-81 [10066740.001]
  • [Cites] Cell Mol Life Sci. 2004 Oct;61(19-20):2614-23 [15526166.001]
  • [Cites] J Mol Histol. 2005 Feb;36(1-2):119-29 [15704006.001]
  • [Cites] Gynecol Oncol. 2005 Mar;96(3):684-94 [15721412.001]
  • [Cites] Cell. 2005 Sep 23;122(6):835-47 [16179254.001]
  • [Cites] Am J Clin Pathol. 2006 Oct;126(4):572-9 [17019794.001]
  • [Cites] Eur J Cancer. 2006 Nov;42(16):2846-54 [16996261.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 [17161157.001]
  • [Cites] Gut. 2007 Jan;56(1):95-106 [16847067.001]
  • [Cites] Differentiation. 2007 Nov;75(9):819-30 [17999741.001]
  • [Cites] Int J Cancer. 2008 Nov 1;123(9):2130-7 [18709641.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):5907-12 [10823943.001]
  • (PMID = 19775429.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / ITGB3 protein, human; 0 / Integrin beta3; 0 / Microfilament Proteins; 0 / Nuclear Proteins; 0 / PRAME protein, human; 148412-71-9 / CAPG protein, human
  • [Other-IDs] NLM/ PMC2754489
  •  go-up   go-down


5. Ninomiya H, Hiramatsu M, Inamura K, Nomura K, Okui M, Miyoshi T, Okumura S, Satoh Y, Nakagawa K, Nishio M, Horai T, Miyata S, Tsuchiya E, Fukayama M, Ishikawa Y: Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. Lung Cancer; 2009 Feb;63(2):235-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type.
  • The presence of epidermal growth factor receptor (EGFR) tyrosine kinase (TK) mutations significantly correlates with tumor sensitivity to TK inhibitors, particularly in lung adenocarcinomas, the predominant histological subtype in Japan and the United States.
  • To clarify links between EGFR mutations and pathological findings in Japanese lung cancer, detailed pathological features of adenocarcinomas were examined using the WHO criteria as well as our cell type classification (hobnail, columnar and polygonal).
  • We conclude that characteristic histological features, i.e. the hobnail cell morphology and the presence of BAC component and MPP are good predictors of EGFR mutations in lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Mutation. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lung Cancer. 2009 Feb;63(2):161-3 [19027983.001]
  • (PMID = 18571764.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


6. Yamamori M, Taniguchi M, Maeda S, Nakamura T, Okamura N, Kuwahara A, Iwaki K, Tamura T, Aoyama N, Markova S, Kasuga M, Okumura K, Sakaeda T: VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese. Int J Med Sci; 2008;5(2):80-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese.
  • BACKGROUND: Previously, MDR1 T-129C polymorphism, encoding multidrug resistant transporter MDR1/P-glycoprotein, was reported to be predictive of poorly-differentiated colorectal adenocarcinomas.
  • Treatment of a colorectal adenocarcinoma cell line, HCT-15, with sodium butyrate, a typical differentiating agent, resulted in an increase of alkaline phosphatase activity and MDR1 mRNA expression, but in a decrease of VEGF mRNA expression.
  • CONCLUSIONS: VEGF T-1498C polymorphism is also a candidate marker predictive of poorly-differentiated colorectal adenocarcinomas, but further investigations with a large number of patients should be addressed to draw a conclusion.
  • [MeSH-major] Adenocarcinoma / genetics. Cell Transformation, Neoplastic / genetics. Colorectal Neoplasms / genetics. Vascular Endothelial Growth Factor A / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Feb;36(2):121-6 [10672056.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2401-7 [10873092.001]
  • [Cites] Biol Pharm Bull. 2006 Jul;29(7):1449-53 [16819187.001]
  • [Cites] Breast Cancer Res Treat. 2000 May;61(1):13-20 [10930086.001]
  • [Cites] Cytokine. 2000 Aug;12(8):1232-5 [10930302.001]
  • [Cites] J Vasc Res. 2000 Nov-Dec;37(6):443-8 [11146397.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Jun;280(6):C1358-66 [11350730.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] Int J Clin Oncol. 2001 Oct;6(5):221-8 [11723743.001]
  • [Cites] J Am Soc Nephrol. 2002 Jan;13(1):260-4 [11752046.001]
  • [Cites] J Cell Sci. 2001 Dec;114(Pt 24):4557-65 [11792820.001]
  • [Cites] Am J Hematol. 2002 Apr;69(4):247-54 [11921018.001]
  • [Cites] Diabetes. 2002 May;51(5):1635-9 [11978667.001]
  • [Cites] Lab Invest. 2002 May;82(5):555-62 [12003996.001]
  • [Cites] J Med Genet. 2002 May;39(5):340-6 [12011154.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):121-8 [12017273.001]
  • [Cites] Genes Immun. 2002 Jun;3(4):229-32 [12058259.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3369-72 [12067976.001]
  • [Cites] Pharm Res. 2002 Sep;19(9):1323-9 [12403069.001]
  • [Cites] Biol Pharm Bull. 2002 Nov;25(11):1391-400 [12419946.001]
  • [Cites] Vascul Pharmacol. 2002 Nov;39(4-5):225-37 [12747962.001]
  • [Cites] World J Gastroenterol. 2003 Jun;9(6):1227-30 [12800229.001]
  • [Cites] FEBS Lett. 2003 Jun 19;545(2-3):144-50 [12804765.001]
  • [Cites] Biochem Pharmacol. 2003 Jul 1;66(1):163-70 [12818377.001]
  • [Cites] Pharmacogenomics. 2003 Jul;4(4):397-410 [12831320.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):468-71 [12845639.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Jun;22(2):229-37 [12866573.001]
  • [Cites] Oncologist. 2004;9 Suppl 1:2-10 [15178810.001]
  • [Cites] Curr Top Med Chem. 2004;4(13):1385-98 [15379652.001]
  • [Cites] J Surg Oncol. 1982 Nov;21(3):143-8 [7132366.001]
  • [Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):254-62 [3134521.001]
  • [Cites] Biochem Biophys Res Commun. 1989 Jun 15;161(2):851-8 [2735925.001]
  • [Cites] J Clin Invest. 1989 Nov;84(5):1470-8 [2478587.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1309-12 [2479987.001]
  • [Cites] Cell. 1991 Jul 12;66(1):85-94 [1712673.001]
  • [Cites] World J Surg. 1995 Mar-Apr;19(2):178-83 [7754620.001]
  • [Cites] Histopathology. 1997 Aug;31(2):123-33 [9279562.001]
  • [Cites] Histol Histopathol. 1998 Oct;13(4):1233-42 [9810514.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1379-84 [9823983.001]
  • [Cites] Int J Cancer. 1999 Jun 11;81(6):845-50 [10362127.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 3;325(1):144-50 [15522212.001]
  • [Cites] Hepatogastroenterology. 2004 Nov-Dec;51(60):1698-702 [15532808.001]
  • [Cites] Drug Metab Pharmacokinet. 2005 Dec;20(6):391-414 [16415525.001]
  • [Cites] Curr Pharm Des. 2006;12(3):273-86 [16454744.001]
  • [Cites] Drug Metab Pharmacokinet. 2006 Apr;21(2):126-32 [16702732.001]
  • (PMID = 18414651.001).
  • [ISSN] 1449-1907
  • [Journal-full-title] International journal of medical sciences
  • [ISO-abbreviation] Int J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Butyrates; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Vascular Endothelial Growth Factor A; EC 3.1.3.1 / Alkaline Phosphatase
  • [Other-IDs] NLM/ PMC2293643
  • [Keywords] NOTNLM ; colorectal adenocarcinoma / differentiation / genetic polymorphism / predictive marker / vascular endothelial growth factor
  •  go-up   go-down


7. Deka J, Wiedemann N, Anderle P, Murphy-Seiler F, Bultinck J, Eyckerman S, Stehle JC, André S, Vilain N, Zilian O, Robine S, Delorenzi M, Basler K, Aguet M: Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas. Cancer Res; 2010 Aug 15;70(16):6619-28
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl9/Bcl9l are critical for Wnt-mediated regulation of stem cell traits in colon epithelium and adenocarcinomas.
  • Adenocarcinomas with aberrant Wnt signaling arose with similar incidence in wild-type and mutant mice.
  • [MeSH-major] Adenocarcinoma / pathology. Colonic Neoplasms / pathology. Intracellular Signaling Peptides and Proteins / metabolism. Neoplastic Stem Cells / pathology. Wnt Proteins / metabolism


8. Wang KL, Wu TT, Resetkova E, Wang H, Correa AM, Hofstetter WL, Swisher SG, Ajani JA, Rashid A, Hamilton SR, Albarracin CT: Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. Clin Cancer Res; 2006 Aug 1;12(15):4598-604
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
  • However, the role of ANXA1 in esophageal adenocarcinoma is unclear.
  • Our goal was to evaluate ANXA1 expression and determine its prognostic significance in adenocarcinoma of the esophagus and esophagogastric junction.
  • EXPERIMENTAL DESIGN: This study included 104 consecutive patients with primary resected esophageal and esophagogastric junction adenocarcinomas (11 stage I, 24 stage II, 53 stage III, and 16 stage IV).
  • CONCLUSION: Our results indicate that high ANXA1 expression is frequent in esophageal and esophagogastric junction adenocarcinomas, correlates with more advanced pathologic T stage and the presence of distant metastasis, and is an independent prognostic factor for patient survival.
  • [MeSH-major] Adenocarcinoma / metabolism. Annexin A1 / biosynthesis. Esophageal Neoplasms / metabolism. Esophagogastric Junction / metabolism. Esophagogastric Junction / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Survival Analysis. Tissue Array Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16899607.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A1
  •  go-up   go-down


9. Gladhaug IP, Westgaard A, Schjølberg AR, Burum-Auensen E, Pomianowska E, Clausen OP: Spindle proteins in resected pancreatic head adenocarcinomas: BubR1 is an independent prognostic factor in pancreatobiliary-type tumours. Histopathology; 2010 Feb;56(3):345-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle proteins in resected pancreatic head adenocarcinomas: BubR1 is an independent prognostic factor in pancreatobiliary-type tumours.
  • The aim was to examine their possible prognostic impact in resected adenocarcinomas in the pancreatic head.
  • METHODS AND RESULTS: Two hundred and eighteen consecutively resected pancreatobiliary-type (n=145) and intestinal-type (n=73) adenocarcinomas involving the pancreatic head were examined for expression of Aurora A, Mad2 and BubR1 by immunohistochemistry on tissue microarrays.
  • CONCLUSION: BubR1 expression is a novel, independent adverse prognostic factor after pancreatoduodenectomy of pancreatobiliary-type adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / analysis. Pancreatic Neoplasms / metabolism. Protein-Serine-Threonine Kinases / biosynthesis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459534.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Cell Cycle Proteins; 0 / MAD2L1 protein, human; 0 / Mad2 Proteins; 0 / Repressor Proteins; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / BUB1 protein, human; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


10. Schildhaus HU, Kröckel I, Lippert H, Malfertheiner P, Roessner A, Schneider-Stock R: Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol; 2005 Jun;26(6):1493-500
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach.
  • Although the incidence of Barrett's carcinomas (BC) and proximal gastric adenocarcinomas (PGC) is increasing, little is known about different epigenetic changes in these etiopathogenetically distinct entities.
  • Therefore, 29 adenocarcinomas [10 BC, 7 PGC and 12 tumors of the esophagogastric junction (JC)] and corresponding non-tumor controls (NT) were examined using methylation-specific PCR.
  • This is the first report on promoter methylation of death-associated protein kinase (DAPK) and fragile histidine triad gene (FHIT) in BC; both DAPK (BC 0.7, JC 0.92 and PGC 0.86) and FHIT (BC 0.88, JC 1.0 and PGC 1.0) were found to be highly methylated, suggesting that epigenetic silencing of these tumor suppressors is a common event in adenocarcinomas of the upper gastrointestinal tract, including BC.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Adenocarcinoma / genetics. Cadherins / genetics. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Methylation. Esophageal Neoplasms / genetics. Esophagogastric Junction. Neoplasm Proteins / genetics. O(6)-Methylguanine-DNA Methyltransferase / genetics. Promoter Regions, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870861.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


11. Afify A, Pang L, Howell L: Diagnostic utility of CD44 standard, CD44v6, and CD44v3-10 expression in adenocarcinomas presenting in serous fluids. Appl Immunohistochem Mol Morphol; 2007 Dec;15(4):446-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of CD44 standard, CD44v6, and CD44v3-10 expression in adenocarcinomas presenting in serous fluids.
  • In contrast to the standard form of CD44, which is almost ubiquitously expressed, splice variants are highly restricted in their expression in normal or malignant tissues.
  • The purpose of this study was to evaluate the extent to which metastatic adenocarcinomas in effusions express CD44s, CD44v6, and CD44v3-10 and to assess their diagnostic utility in distinguishing reactive mesothelial cells from adenocarcinomas.
  • Archival paraffin-embedded cell blocks of serous fluids from 23 cases of benign effusions containing reactive mesothelial cells and 45 cases of malignant effusions with metastatic adenocarcinoma (18 ovarian, 11 pulmonary, 9 gastrointestinal, and 7 breast) were retrieved from the surgical pathology files.
  • The cytopathology of all cases was reviewed to confirm the diagnosis.
  • In contrast neoplastic cells in malignant effusions expressed CD44s in 11 cases (24%), CD44v6 in 21 cases (47%), and CD44v3-10 in 39 cases (87%).
  • CD44s immunostaining can be used as a reliable marker to identify reactive mesothelial cells, meanwhile CD44v3-10 immunostaining can detect majority of adenocarcinomas in malignant effusions.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091389.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human; 0 / CD44v6 antigen; 0 / Glycoproteins
  •  go-up   go-down


12. Krusche CA, Vloet AJ, Classen-Linke I, von Rango U, Beier HM, Alfer J: Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas. Hum Reprod; 2007 Nov;22(11):2956-66
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas.
  • Recently, HDAC inhibitors were shown to enhance differentiation of endometrial fibroblasts and endometrial adenocarcinomas.
  • In endometrial adenocarcinomas (n = 17), HDAC-1 expression was studied by immunohistochemistry.
  • Compared to normal endometrium, a high proportion of endometrial adenocarcinomas showed impaired HDAC-1 protein expression in the epithelial and stromal compartment.
  • [MeSH-major] Adenocarcinoma / enzymology. Endometrial Neoplasms / enzymology. Endometrium / enzymology. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17728353.001).
  • [ISSN] 0268-1161
  • [Journal-full-title] Human reproduction (Oxford, England)
  • [ISO-abbreviation] Hum. Reprod.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Repressor Proteins; EC 2.3.1.48 / p300-CBP Transcription Factors; EC 2.3.1.48 / p300-CBP-associated factor; EC 3.5.1.98 / HDAC1 protein, human; EC 3.5.1.98 / Histone Deacetylase 1; EC 3.5.1.98 / Histone Deacetylase 2; EC 3.5.1.98 / Histone Deacetylases; EC 3.5.1.98 / histone deacetylase 3
  •  go-up   go-down


13. Godoy MC, Naidich DP: Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management. Radiology; 2009 Dec;253(3):606-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subsolid pulmonary nodules and the spectrum of peripheral adenocarcinomas of the lung: recommended interim guidelines for assessment and management.
  • These are now known to frequently, although not invariably, fall into the spectrum of peripheral adenocarcinomas of the lung.
  • As a consequence, recognition of the potential association between subsolid nodules and peripheral adenocarcinomas requires a review of current guidelines for the management of these lesions, further necessitated by a differential diagnosis that includes benign lesions such as focal inflammation, focal fibrosis, and organizing pneumonia.
  • [MeSH-major] Adenocarcinoma / radiography. Lung Neoplasms / radiography. Practice Guidelines as Topic. Solitary Pulmonary Nodule / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Imaging, Three-Dimensional. Incidence. Prognosis. Radiographic Image Interpretation, Computer-Assisted. Tomography, Emission-Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952025.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 87
  •  go-up   go-down


14. Ogawa T, Yoshida T, Tsuruta T, Tokuyama W, Adachi S, Kikuchi M, Mikami T, Saigenji K, Okayasu I: Tumor budding is predictive of lymphatic involvement and lymph node metastases in submucosal invasive colorectal adenocarcinomas and in non-polypoid compared with polypoid growths. Scand J Gastroenterol; 2009;44(5):605-14
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor budding is predictive of lymphatic involvement and lymph node metastases in submucosal invasive colorectal adenocarcinomas and in non-polypoid compared with polypoid growths.
  • OBJECTIVE: Early colorectal carcinomas (submucosal invasive adenocarcinomas) can be classified into polypoid and non-polypoid growth types, the latter progressing more rapidly to advanced malignancy.
  • Tumor budding was examined using anti-cytokeratin antibodies in 98 colorectal submucosal invasive adenocarcinomas and compared with the clinicopathological findings.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Polyps / pathology. Colorectal Neoplasms / pathology. Lymph Nodes / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Confidence Intervals. Disease Progression. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Logistic Models. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Odds Ratio. Predictive Value of Tests. Probability. Registries. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Tumor Burden

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19221929.001).
  • [ISSN] 1502-7708
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


15. Hu M, Yu J, Liu N, Kong L, Zhang P: The role of whole body &lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT scan in patients with carcinoma of unknown primary. J Clin Oncol; 2009 May 20;27(15_suppl):e22051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Difficult challenges in oncology which the identification of the primary tumor and a complete disease staging could offer a more rational and efficient treatment in order to improve the survival time.
  • In 60 (51.28%) patients, the primary tumor site was not localized modifying the stage of disease.
  • Between the adenocarcinoma and squamous cell carcinoma groups, no significant difference in SUVmax was found ( t=1.191, p = 0.244).
  • CONCLUSIONS: Our data strongly support <sup>18</sup>F-FDG PET/ CT imagings not only provide new insights in the diagnosis and staging of patients with CUP, but also evaluate biologic characters of tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963233.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kosty MP, Kumar P, Wozniak A, Jahanzeb M, Chung C, Wang L, Sing A, Lynch T, ARIES Investigators: Development of cavitation while on bevacizumab (BV) therapy in patients (pts) with non-small cell lung cancer (NSCLC): Results from ARIES-A bevacizumab (BV) treatment observational cohort study (OCS). J Clin Oncol; 2009 May 20;27(15_suppl):e19045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Evaluable pts had measurable disease at BL and at least one-post-BL scan.
  • Key BL characteristics for the substudy and overall cohorts, respectively, include: 44% vs 51% ≥65 yrs; 67% vs 67% adenocarcinoma; 6% vs 5% therapeutic AC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962105.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Marginean EC, Torlakovic G, Neufeld H, Torlakovic E: Association of upregulated GATA-4 transcription factor colorectal adenocarcinoma with metastatic and primary tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of upregulated GATA-4 transcription factor colorectal adenocarcinoma with metastatic and primary tumors.
  • Its protein expression in colonic adenocarcinoma has not been systematically evaluated and small number of samples was previously reported as negative.
  • METHODS: Forty cases of colorectal adenocarcinoma were evaluated.
  • RESULTS: GATA-4 was expressed in 32% of colorectal adenocarcinoma, but not in benign colonic mucosa (p=0.0001, Chi-Square).
  • GATA-4 was also significantly more expressed in metastatic (41%) than in primary (21%) colorectal adenocarcinoma (p<0.0001, Chi-Square).
  • NF-B activation was not present in any of the samples of benign colonic mucosa, but it was detected in 64% adenocarcinomas (p<0.0001, Chi-Square).
  • While there was no difference in NF-B activation between primary vs. metastatic adenocarcinoma, a strong positive association between GATA-4 expression and NF-B activation (p<0.0001, Linear-by- Linear) was found.
  • GATA-4 may have a role in colorectal adenocarcinoma development and progression and it should be further evaluated in prospective studies as a putative adverse prognostic factor in colorectal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964606.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Resnick MB, Gavilanez M, Newton E, Konkin T, Bhattacharya B, Britt DE, Sabo E, Moss SF: Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol; 2005 Aug;36(8):886-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation.
  • Tissue microarrays were created from paraffinized samples from 146 patients with distal gastric adenocarcinomas (61 intestinal and 85 diffuse or mixed subtypes).
  • Moderate to strong staining of claudins 1, 3, 4, and ZO-1 was detected in 74%, 48%, 62%, and 74% of the intestinal but in only 46%, 24%, 45%, and 36% of the diffuse subtype of adenocarcinomas (P < .05).
  • Cox multivariate analysis revealed that tumor stage, diffuse subtype, and moderate to strong claudin 4 staining were associated with decreased survival (P < .02).
  • In conclusion, claudins 1, 3, and 4 and ZO-1 are strongly expressed in most gastric intestinal-type adenocarcinomas but less frequently in diffuse gastric cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Membrane Proteins / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112005.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 5 P20 RR017596-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / TJP1 protein, human; 0 / Zonula Occludens-1 Protein
  •  go-up   go-down


19. Jung JH, Jung CK, Choi HJ, Jun KH, Yoo J, Kang SJ, Lee KY: Diagnostic utility of expression of claudins in non-small cell lung cancer: different expression profiles in squamous cell carcinomas and adenocarcinomas. Pathol Res Pract; 2009;205(6):409-16
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of expression of claudins in non-small cell lung cancer: different expression profiles in squamous cell carcinomas and adenocarcinomas.
  • Claudin-1 expression was stronger in squamous cell carcinomas than in adenocarcinomas, whereas claudin-4 and claudin-5 expression was stronger in adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Lung Neoplasms / metabolism. Membrane Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Claudin-1. Claudin-3. Claudin-4. Claudin-5. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Korea. Male. Middle Aged. Neoplasm Staging. Tissue Array Analysis. Young Adult

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231096.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN5 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudin-5; 0 / Membrane Proteins
  •  go-up   go-down


20. Yamada N, Kusumoto M, Maeshima A, Suzuki K, Matsuno Y: Correlation of the solid part on high-resolution computed tomography with pathological scar in small lung adenocarcinomas. Jpn J Clin Oncol; 2007 Dec;37(12):913-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of the solid part on high-resolution computed tomography with pathological scar in small lung adenocarcinomas.
  • OBJECTIVE: To predict the grade of invasion in small (</=3 cm in diameter) lung adenocarcinomas from preoperative high-resolution computed tomography (HRCT), we measured CT numbers of the solid part and compared these with pathological features.
  • METHODS: We reviewed 131 cases of lung adenocarcinoma (</=3 cm in diameter) surgically resected between January 1999 and December 2000, which had >10% ground glass opacity (GGO) area on HRCT.
  • CONCLUSIONS: Small lung adenocarcinomas with a solid part CT number under -40 in on HRCT usually show no invasion or micro-invasion.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18211981.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Ebert MP, Model F, Mooney S, Hale K, Lograsso J, Tonnes-Priddy L, Hoffmann J, Csepregi A, Röcken C, Molnar B, Schulz HU, Malfertheiner P, Lofton-Day C: Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology; 2006 Nov;131(5):1418-30
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas.
  • METHODS: Using methylation-specific arbitrarily primed polymerase chain reaction, a fragment of the Aristaless-like homeobox-4 (ALX4) gene that was highly methylated in colon adenomas and cancer was identified.
  • Methylation of ALX4 was analyzed in colorectal adenomas and cancers, in the liver metastases of patients with colorectal cancer, and in 61 other neoplasias, including gastric, esophageal, and hepatocellular cancer and cholangiocarcinoma.
  • RESULTS: ALX4 gene methylation was confirmed in colon adenomas (11/13) and more frequently present in primary colorectal cancers (30/47) compared with the normal colon mucosa (0/21) (P < .0001).
  • In addition, ALX4 methylation was frequently observed in adenocarcinomas of the esophagus (12/14), stomach (11/15), and bile ducts (4/5) compared with all other cancers (P < .001).
  • CONCLUSIONS: Apart from colon adenomas and primary and metastatic colorectal cancers, ALX4 is frequently methylated in adenocarcinomas of the gastrointestinal tract.
  • [MeSH-major] Adenocarcinoma / genetics. Colorectal Neoplasms / genetics. DNA-Binding Proteins / genetics. Transcription Factors / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Colonic Polyps / genetics. DNA Methylation. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Neoplasm Metastasis. Precancerous Conditions / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101318.001).
  • [ISSN] 0016-5085
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ALX4 protein, human; 0 / DNA-Binding Proteins; 0 / Transcription Factors
  •  go-up   go-down


22. van Dekken H, Tilanus HW, Hop WC, Dinjens WN, Wink JC, Vissers KJ, van Marion R: Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction. Cancer Genet Cytogenet; 2009 Feb;189(1):37-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction.
  • Survival rates of adenocarcinomas of the gastroesophageal junction (GEJ) are low, because these tumors are generally in an advanced stage by the time they are detected.
  • To delineate overexpressed genes, we performed array comparative genomic hybridization (aCGH) and mRNA expression analysis of 15 GEJ adenocarcinoma samples using a fine-tiling cDNA array covering chromosome segments 1q31.3~q41 (193.9-215.8 Mb: 21.9 Mb), 7q11.23~q22.1 (72.3-103.0 Mb: 30.7 Mb), and 8p23.1~p21.3 (11.1-20.7 Mb: 9.6 Mb).
  • In conclusion, using a straightforward approach we constructed a targeted gene profile for GEJ adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 7 / genetics. Chromosomes, Human, Pair 8 / genetics. Esophageal Neoplasms / genetics. Esophagogastric Junction / metabolism. Stomach Neoplasms / genetics
  • [MeSH-minor] Comparative Genomic Hybridization. Female. Gene Expression Profiling. Genome, Human. Humans. Male. Middle Aged. Neoplasm Proteins / analysis. Neoplasm Proteins / genetics. Oligonucleotide Array Sequence Analysis. RNA, Messenger / metabolism


23. Pineda-Daboin K, Neto A, Ochoa-Perez V, Luna MA: Nasopharyngeal adenocarcinomas: a clinicopathologic study of 44 cases including immunohistochemical features of 18 papillary phenotypes. Ann Diagn Pathol; 2006 Aug;10(4):215-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal adenocarcinomas: a clinicopathologic study of 44 cases including immunohistochemical features of 18 papillary phenotypes.
  • Nasopharyngeal adenocarcinomas (NPACs) are uncommon neoplasms with a diverse histomorphology and clinical behavior.
  • There were 28 salivary gland type, 13 conventional low-grade papillary NPACs of surface origin, and 3 metastatic adenocarcinomas, 2 thyroid and 1 lung.
  • In contrast, 18 (64.2%) of the 28 patients with salivary gland-type NPACs had died of the disease or were living with disease at follow-up.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Immunoenzyme Techniques / methods. Nasopharyngeal Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Phenotype. Retrospective Studies. Salivary Glands / chemistry. Salivary Glands / pathology. Survival Rate. Thyroid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844563.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


24. Crist KA, Zhang Z, You M, Gunning WT, Conran PB, Steele VE, Lubet RA: Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture. Carcinogenesis; 2005 May;26(5):951-7
Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of rat ovarian adenocarcinomas developed in response to direct instillation of 7,12-dimethylbenz[a]anthracene (DMBA) coated suture.
  • Human ovarian cancer is predominantly of epithelial cell origin (>90% of malignant tumors) and most often presents at an advanced stage with poor prognosis.
  • Most animal models of ovarian carcinoma yield thecal/granulosa cell tumors, rather than adenocarcinomas.
  • Induction of adenocarcinoma in 10-45% of rats following an ovarian implantation of 7,12-dimethylbenz[a]anthracene (DMBA) coated silk suture has been reported.
  • Tumor histology was distributed as well differentiated adenocarcinoma (1/23), poorly differentiated adenocarcinoma (8/23), thecal/granulosa cell tumor (8/23), undifferentiated sarcoma (5/23) and one undifferentiated carcinoma with no adeno character.
  • Adenocarcinomas appeared to originate from the ovarian surface epithelium, with focal papillary extension into cystic space.
  • Vimentin positive epithelial cells when present in adenocarcinomas (4/7), showed perinuclear staining, quite distinct from the uniformly stained stromal cells in thecal/granulosa cell tumors (8/8).
  • [MeSH-major] 9,10-Dimethyl-1,2-benzanthracene / pharmacology. Adenocarcinoma / chemically induced. Carcinogens / pharmacology. Ovarian Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15695234.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CN / N01-CN-05103
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene
  •  go-up   go-down


25. Shimizu K, Itsuzaki Y, Fujii H, Honoki K, Tsujiuchi T: Reduced expression of the Rassf1a gene and its aberrant DNA methylation in pancreatic duct adenocarcinomas induced by N-nitrosobis(2-oxopropyl)amine in hamsters. Mol Carcinog; 2008 Feb;47(2):80-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced expression of the Rassf1a gene and its aberrant DNA methylation in pancreatic duct adenocarcinomas induced by N-nitrosobis(2-oxopropyl)amine in hamsters.
  • Alterations of the Rassf1a gene were investigated in pancreatic duct adenocarcinomas (PDAs) induced by N-nitrosobis(2-oxopropyl)amine (BOP) in hamsters.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinogens / toxicity. DNA Methylation. Nitrosamines / toxicity. Pancreatic Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17849420.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / DNA Primers; 0 / Nitrosamines; 0 / Tumor Suppressor Proteins; 60599-38-4 / nitrosobis(2-oxopropyl)amine
  •  go-up   go-down


26. Alberty J, Möllers A, Stoll W: [Expert assessment of adenocarcinomas of the nasal cavity and the paranasal sinuses caused by wood dust]. Laryngorhinootologie; 2009 Feb;88(2):106-11
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expert assessment of adenocarcinomas of the nasal cavity and the paranasal sinuses caused by wood dust].
  • BACKGROUND: Adenocarcinomas of the nasal cavity and the paranasal sinuses after occupational exposure to sawdust from oak and beech have been listed as occupational diseases in Germany since 1988.
  • MATERIALS AND METHODS: A retrospective analysis of 43 cases which had been evaluated between March 1994 and February 2007 for an occupational disease #4203, in the Ear-Nose-Throat clinic of the Münster University Hospital, Germany.
  • CONCLUSIONS: The use of the revised guidelines is recommended for expert assessment of adenocarcinomas of the nasal cavity and the paranasal sinuses caused by wood dust.
  • [MeSH-major] Adenocarcinoma / etiology. Dust. Expert Testimony / legislation & jurisprudence. Nasal Cavity. Nose Neoplasms / etiology. Occupational Diseases / etiology. Occupational Exposure / adverse effects. Paranasal Sinus Neoplasms / etiology. Wood / adverse effects
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Postoperative Complications / diagnosis. Postoperative Complications / etiology. Practice Guidelines as Topic. Radiation Injuries / diagnosis. Radiation Injuries / etiology. Radiotherapy, Adjuvant. Retrospective Studies. Workers' Compensation / legislation & jurisprudence

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18651374.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dust
  •  go-up   go-down


27. Servarayan CM, Chandramohan A, Datta D, Manickavasagam K: p53 and its influence in adenocarcinoma stomach. J Clin Oncol; 2009 May 20;27(15_suppl):e15685

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and its influence in adenocarcinoma stomach.
  • Various pathogenesis have been given for the adenocarcinoma, like mutation in the E-catherin gene, amplification of COX-2, HGF/ SF, VEGF; deletion of FHIT, APC, p53 but none have provided a definite target for treatment.
  • METHODS: This is a immunohistochemical prospective experiment study done on 76 cases of Gastric Adenocarcinoma.The location of the tumors were recorded as in the proximal stomach (fundus and body) and distal stomach (antrum, prepylorus, and pylorus).
  • 33 out of 60 (55%)of the males and 8 out of 16 (50%) females were reported of having gastric adenocarcinoma with p53expression.
  • The histology of the tissue samples from the gastric adenocarcinoma patients had following relationship with the p53 immunoreactivity, 20 out of 37 cases(54.05%) of the well differentiated,7 out of 17 cases (41.18% )of the moderately differentiated, and and 13 out of 21 cases(61.90%) of the poorly differentiated gastric adenocarcinoma showed positive immunoreactivity.
  • 52.63 % of the non-mucinous type of gastric adenocarcinoma showed positive p53 immunoreactivity.
  • The mutation is more marked in the poorly differentiated gastric adenocarcinoma.
  • The antral, pylorus,and the prepyloric parts of the stomach( the distal stomach) are more prone for mutated p53 induced adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Cook MB, Kamangar F, Whiteman DC, Freedman ND, Gammon MD, Bernstein L, Brown LM, Risch HA, Ye W, Sharp L, Pandeya N, Webb PM, Wu AH, Ward MH, Giffen C, Casson AG, Abnet CC, Murray LJ, Corley DA, Nyrén O, Vaughan TL, Chow WH: Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst; 2010 Sep 8;102(17):1344-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium.
  • BACKGROUND: Previous studies that showed an association between smoking and adenocarcinomas of the esophagus and esophagogastric junction were limited in their ability to assess differences by tumor site, sex, dose-response, and duration of cigarette smoking cessation.
  • METHODS: We used primary data from 10 population-based case-control studies and two cohort studies from the Barrett's Esophagus and Esophageal Adenocarcinoma Consortium.
  • Patients were classified as having esophageal adenocarcinoma (n = 1540), esophagogastric junctional adenocarcinoma (n = 1450), or a combination of both (all adenocarcinoma; n = 2990).
  • Associations between pack-years of cigarette smoking and risks of adenocarcinomas were assessed, as well as their potential modification by sex and duration of smoking cessation.
  • RESULTS: The summary odds ratios demonstrated strong associations between cigarette smoking and esophageal adenocarcinoma (OR = 1.96, 95% confidence interval [CI] = 1.64 to 2.34), esophagogastric junctional adenocarcinoma (OR = 2.18, 95% CI = 1.84 to 2.58), and all adenocarcinoma (OR = 2.08, 95% CI = 1.83 to 2.37).
  • Compared with current smokers, longer smoking cessation was associated with a decreased risk of all adenocarcinoma after adjusting for pack-years (<10 years of smoking cessation: OR = 0.82, 95% CI = 0.60 to 1.13; and > or =10 years of smoking cessation: OR = 0.71, 95% CI = 0.56 to 0.89).
  • CONCLUSIONS: Cigarette smoking is associated with increased risks of adenocarcinomas of the esophagus and esophagogastric junction in white men and women; compared with current smoking, smoking cessation was associated with reduced risks.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Quitting Smoking.
  • MedlinePlus Health Information. consumer health - Smoking.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Br J Cancer. 2009 Sep 1;101(5):855-9 [19672254.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2001 Feb;110(2):190-3 [11219528.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Gastroenterology. 2001 Dec;121(6):1286-93 [11729107.001]
  • [Cites] Am J Clin Nutr. 2002 Jan;75(1):137-44 [11756071.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):860-8 [12115489.001]
  • [Cites] Am J Epidemiol. 2002 Nov 1;156(9):813-23 [12396999.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] BMJ. 2003 Sep 6;327(7414):557-60 [12958120.001]
  • [Cites] Nat Rev Cancer. 2003 Oct;3(10):733-44 [14570033.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):826-34 [15173266.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;83:1-1438 [15285078.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 15;96(18):1383-7 [15367571.001]
  • [Cites] J Natl Cancer Inst. 1994 Sep 7;86(17):1340-5 [8064893.001]
  • [Cites] Cancer Causes Control. 1994 Jul;5(4):333-40 [8080945.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] Am J Gastroenterol. 1995 Oct;90(10):1785-90 [7572895.001]
  • [Cites] Int J Cancer. 1997 Aug 7;72(4):565-73 [9259392.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Am J Epidemiol. 1999 Sep 1;150(5):469-75 [10472946.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):620-5 [15767340.001]
  • [Cites] Cancer Causes Control. 2005 Nov;16(9):1065-74 [16184472.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):517-23 [16537710.001]
  • [Cites] Am J Epidemiol. 2006 Jun 1;163(11):1053-64 [16624970.001]
  • [Cites] Dis Esophagus. 2006;19(5):321-8 [16984526.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10):1585-94 [17461453.001]
  • [Cites] Am J Epidemiol. 2007 Jun 15;165(12):1424-33 [17420181.001]
  • [Cites] Am J Epidemiol. 2007 Aug 15;166(4):479-89 [17548786.001]
  • [Cites] Epidemiology. 2007 Sep;18(5):639-48 [17700253.001]
  • [Cites] Epidemiology. 2007 Sep;18(5):649-51 [17700254.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2007 Nov 9;56(44):1157-61 [17989644.001]
  • [Cites] Int J Cancer. 2008 Mar 1;122(5):1118-29 [17990321.001]
  • [Cites] Gut. 2008 Feb;57(2):173-80 [17932103.001]
  • [Cites] Nicotine Tob Res. 2008 Feb;10(2):287-99 [18236293.001]
  • [Cites] Eur J Cancer. 2008 Feb;44(3):465-71 [18221867.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):352-8 [18268119.001]
  • [Cites] Gut. 2008 Mar;57(3):298-305 [17965056.001]
  • [Cites] Am J Epidemiol. 2008 Apr 15;167(8):970-5 [18250081.001]
  • [Cites] Lancet Oncol. 2008 Jul;9(7):649-56 [18556244.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1184-7 [18695138.001]
  • [Cites] Gastroenterol Clin North Am. 2009 Mar;38(1):27-57, vii [19327566.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1174-82 [19293308.001]
  • [Cites] Br J Cancer. 2000 Jul;83(1):127-32 [10883680.001]
  • (PMID = 20716718.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA057949-03; United States / PHS HHS / / R21DKO77742; United States / NCI NIH HHS / CA / U01-CA57923; United States / NCI NIH HHS / CA / U01-CA57983; United States / NIDDK NIH HHS / DK / R01 DK063616; United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NCI NIH HHS / CA / K05 CA124911; United States / NCI NIH HHS / CA / U01-CA57949; United States / NCI NIH HHS / CA / CA59636; United States / NCI NIH HHS / CA / R01-CA30022; United States / NCI NIH HHS / CA / U01 CA057949; United Kingdom / Medical Research Council / / ; United States / NCI NIH HHS / CA / R01 CA57947-03; United States / Intramural NIH HHS / / ZIA CP010136-15; United States / NCI NIH HHS / CA / R37-CA41530; United Kingdom / Chief Scientist Office / /
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2935475
  •  go-up   go-down


29. Marxfeld H, Staedtler F, Harleman JH: Gene expression in fibroadenomas of the rat mammary gland in contrast to spontaneous adenocarcinomas and normal mammary gland. Exp Toxicol Pathol; 2006 Nov;58(2-3):145-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression in fibroadenomas of the rat mammary gland in contrast to spontaneous adenocarcinomas and normal mammary gland.
  • However, the entity adenocarcinoma arising in fibroadenoma does exist and in humans there is evidence of certain forms of fibroadenomas to confer greater risk of subsequent breast cancer.
  • In this study, we aim to elucidate the molecular features of both spontaneous fibroadenomas and adenocarcinomas.
  • We conclude that in the tumours examined here, no progression to adenocarcinoma is likely.
  • Further studies are needed, examining a greater number of tumours and including cases of adenocarcinoma arising in fibroadenoma.
  • [MeSH-major] Adenocarcinoma / genetics. Fibroadenoma / genetics. Gene Expression Profiling. Mammary Glands, Animal / metabolism. Mammary Neoplasms, Animal / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16905299.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Thy-1; 9007-34-5 / Collagen; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


30. Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester T: Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis Esophagus; 2007;20(1):36-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia?
  • Adenocarcinoma of the distal esophagus and gastroesophageal junction are believed to arise in Barrett's esophagus with intestinal metaplasia.
  • Whether adenocarcinoma can arise in columnar lined esophagus without intestinal metaplasia is in doubt.
  • Whether adenocarcinoma of the gastric cardia arises in intestinal metaplasia of the gastric cardia is also in doubt.
  • We aim to evaluate the relationship of size and stage of adenocarcinoma of the distal esophagus, gastroesophageal junction and gastric cardia to intestinal metaplasia and other types of columnar epithelium.
  • Seventy-four patients who had esophagogastrectomy for adenocarcinomas in this region were examined histologically to assess the frequency of residual intestinal metaplasia in the surrounding epithelium.
  • These data strongly support the contention that adenocarcinomas of this region, including those in the gastric cardia, arise in intestinal metaplastic epithelium.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227308.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. von Rahden BH, Stein HJ, Feith M, Becker K, Siewert JR: Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. J Clin Oncol; 2005 Feb 1;23(4):874-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction.
  • PURPOSE: To evaluate the value of lymphatic vessel invasion (LVI) as a predictor of survival in patients with primary resected adenocarcinomas of the esophagogastric junction (AEG).
  • PATIENTS AND METHODS: We prospectively evaluated 459 patients undergoing primary surgical resection for tumors of the esophagogastric junction at our institution between 1992 and 2000 (180 adenocarcinomas of the distal esophagus, AEG I; 140 carcinomas of the cardia, AEG II; and 139 subcardial gastric cancers, AEG III).
  • [MeSH-major] Adenocarcinoma / pathology. Esophageal Neoplasms / pathology. Esophagogastric Junction. Lymphatic Vessels / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Prognosis. Prospective Studies

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15681533.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Lai TC, Chow KC, Lin TY, Chiang IP, Fang HY, Chen CY, Ho SP: Expression of 53BP1 as a cisplatin-resistant marker in patients with lung adenocarcinomas. Oncol Rep; 2010 Aug;24(2):321-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of 53BP1 as a cisplatin-resistant marker in patients with lung adenocarcinomas.
  • DNA repair is one of the major causes of spontaneous drug and radiation resistance in patients with lung adenocarcinomas (LADC).
  • [MeSH-major] Adenocarcinoma / genetics. Cisplatin / therapeutic use. Drug Resistance, Neoplasm / genetics. Intracellular Signaling Peptides and Proteins / genetics. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596616.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Pharmacological; 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / TP53BP1 protein, human; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Terry MB, Gammon MD, Zhang FF, Vaughan TL, Chow WH, Risch HA, Schoenberg JB, Mayne ST, Stanford JL, West AB, Rotterdam H, Blot WJ, Fraumeni JF Jr, Santella RM: Alcohol dehydrogenase 3 and risk of esophageal and gastric adenocarcinomas. Cancer Causes Control; 2007 Nov;18(9):1039-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol dehydrogenase 3 and risk of esophageal and gastric adenocarcinomas.
  • OBJECTIVES: Alcohol increases esophageal squamous carcinoma risk but has been less consistently associated with esophageal adenocarcinoma.
  • METHODS: We undertook a study to examine whether a common polymorphism in the alcohol dehydrogenase 3 gene was associated with a higher risk of esophageal adenocarcinoma using data and biological samples collected for the Esophageal and Gastric Cancer Study (n = 114 esophageal and gastric cardia adenocarcinoma, n = 60 non-cardia gastric carcinoma, n = 23 cases of esophageal squamous cell carcinoma and 160 controls).
  • RESULTS: Individuals homozygous for ADH ( 3 ) (1-1) had a higher risk of each tumor type compared to individuals who had ADH ( 3 ) (2-2) or ADH ( 3 ) (1-2) genotype (OR = 1.7, 95% CI = 1.0-2.9 for esophageal and gastric cardia adenocarcinomas; OR = 1.7, 95% CI = 0.7-4.3 for esophageal squamous cell carcinoma; and OR = 2.8, 95% CI = 1.5-5.1 for non-cardia gastric cancer).
  • CONCLUSION: These data suggest ADH3 genotype may be associated with risk of esophageal and gastric cardia adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17665311.001).
  • [ISSN] 0957-5243
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01-CA57923; United States / NCI NIH HHS / CA / U01-CA57983; United States / NCI NIH HHS / CN / N01-CN05230; United States / NCI NIH HHS / CA / U01-CA57949; United States / NCI NIH HHS / CP / N02-CP40501; United States / NIEHS NIH HHS / ES / P30-ES09089; United States / NIEHS NIH HHS / ES / P30-ES10126; United States / NIEHS NIH HHS / ES / P30 ES009089
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 1.1.1.1 / ADH1C protein, human; EC 1.1.1.1 / Alcohol Dehydrogenase
  •  go-up   go-down


34. Yuan Y, Ma H, Cohen DJ, Ryan T, Choi H, Love' E, Awad M, Khambata-Ford S, Mauro D, Hochster H: Activity and tolerance of biweekly CapeOx-cetuximab in 1st line therapy of metastatic colorectal cancer (mCRC): Relation to K-ras mutation status. J Clin Oncol; 2009 May 20;27(15_suppl):e15018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts with previously untreated, histologically confirmed, metastatic colon adenocarcinoma, ECOG PS 0-1, and adequate organ function were eligible.
  • Of 23 pts evaluable for response, there were 2 CR, 12 PR, and 3 SD (ORR 61%; disease control rate (DCR) 74%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964423.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Sonpavde G, Frolov A, Macdonell V, Hayes TG, Mims MP, Ayala GE, Wheeler TM, Thompson TC, Ittman MM, Kadmon D: Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP). J Clin Oncol; 2009 May 20;27(15_suppl):5127

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological evidence of adenocarcinoma of the prostate was required with clinical stage T<sub>1c</sub> or T<sub>2a</sub> with Gleason 8-10 disease, or clinical stage T<sub>2b</sub>-T<sub>2c</sub> with Gleason grade 7 and PSA of >10 ng/mL, or clinical stage T<sub>3</sub>.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Hwang JY, Yoo C, Kim T, Lee J, Park D, Seo D, Lee S, Kim M, Han D, Kim S, Lee J: A randomized phase II study of FOLFOX or FOLFIRI.3 as second-line therapy in patients with advanced pancreatic cancer previously treated with gemcitabine-based chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):4618

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with advanced pancreatic adenocarcinoma previously treated with gemcitabine were randomly assigned to FOLFOX or FOLFIRI.3 stratifying by age (≤ 65 vs. >65), performance status (0-1 vs. 2) and prior response to gemcitabine (PR/SD vs. PD).
  • Disease control (PR+SD) was achieved in 20% (5/25 in FOLFOX) and 28% (7/25 in FOLFIRI.3) of patients with measurable disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964179.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Luttgen MS, Marrinucci D, Lazar D, Malchiodi M, Clark P, Huynh E, Bethel K, Bazhenova L, Nieva J, Kuhn P: Circulating tumor cells monitored over time in lung cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):11025

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological subtypes in the 42 cases for which the data was available included adenocarcinoma (22/42), squamous cell carcinoma (6/42), large cell undifferentiated carcinoma (3/42), and non-small cell lung carcinoma not further described, poorly differentiated, or with a mixed pattern (11/42).
  • Five of the 6 patients (83.3%) clinically showing progressive disease at the 3 mo time point show an increase in CTC count between time 0 and 3 mo.
  • CONCLUSIONS: CTCs can be effectively enumerated in metastatic NSCLC patients, with the majority demonstrating CTCs in the setting of progressive disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963968.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Arnaoutakis K, Morse AB, Ambika S, Wong G, Parameswaran R: Practice-based improvement (PBI) via web based tool (WBT) in multidisciplinary gynecologic oncology clinic (MGOC). J Clin Oncol; 2009 May 20;27(15_suppl):e17545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Part 1 evaluation showed that 68 % pts had endometrial adenocarcinoma; 20% cervical cancer; 12% uterine sarcoma or carcinosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963762.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Tojo T, Tojo T, Naito H, Kimura M, Takasawa S, Dohi Y, Nagata Y, Taniguchi S: Regenerating gene 1α (REG 1α) expression and new treatment strategies in early non-small cell lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22178

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We enrolled 70 NSCLCs (adenocarcinoma (AC)(n=48) and squamous cell carcinoma (SCC)(n=22)) who received surgery at Nara Medical University Hospital.
  • After median follow-up of 26.2 months, 12 patients died due to disease progression.
  • Disease free survival of REG 1α positive patients was also worse than negative patients in ACs (P<0.05) and SCCs (P=0.16).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963718.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Perazzo F, Denninghoff V, Pasccon G, Pallotta MG, Tatangelo M, Cuartero V, Kirchuck R, Chacón M, Gennari L, Vera K, Avagnina A: Preliminary report of the mutation status of KRAS and BRAF-V600E in an Argentinean population of primary colorectal tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e22183

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenocarcinoma was the unique histotype and mucinous differentiation was observed in 14.7% (21).
  • The Pathological Stage at diagnosis was Stage I 3.42% (5), II 24% (35), III 33.6% (49) and IV 39% (57).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963599.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Quesenberry PJ, Del Tatto M, Berz D, Miner T, Ng T, Winer ES, Aliotta J, Colvin G, Dooner M, Dooner G, Fontaine JP: Marrow cell genetic phenotype change induced by human lung cancer cells. J Clin Oncol; 2009 May 20;27(15_suppl):11108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Lung cancers studied were adenocarcinoma, endobronchial alveolar carcinoma, bronchioloalveolar carcinoma, non-small cell carcinoma and squamous cell carcinoma. mRNAs for aquaporin 1-5, specific for type I pneumocytes and surfactant A-D, specific for type II pneumocytes, were measured.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963460.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Sugarbaker DJ, Tilleman TR, Swanson SJ, Jaklitsch MT, Mentzer SJ, Mujoomdar AA, Bueno R: The role of extrapleural pneumonectomy in the management of pleural cancers. J Clin Oncol; 2009 May 20;27(15_suppl):7577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For all cases, the site of disease involved a single pleura.
  • Twenty-eight patients had stage IIIB (T4-N0-1) lung adenocarcinoma representing the largest homogeneous group of patients by cell type and stage.
  • Absence of residual nodal disease at resection is positively correlated with survival in the stage IIIB NSCLC group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963385.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Kubota K, Kunitoh H, Seto T, Shimada N, Tsuboi M, Okamoto H, Masuda N, Maruyama R, Shibuya M, Watanabe K: A randomized phase II trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CIS) versus paclitaxel (PAC) plus carboplatin (CAR) in patients with completely resected non-small cell lung cancer (NSCLC): Safety and feasibility data from trial TORG 0503. J Clin Oncol; 2009 May 20;27(15_suppl):7561

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients' demographics (DC/PA): median age 63/59 years, 60%/66% male, 17%/22% PS 1, 79%/73% adenocarcinoma, 40%/40% of patients were stage IB/IIA, 60%/60% IIB/IIIA.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963338.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Casal J, Vázquez S, León L, Lázaro M, Fírvida JL, Amenedo M, Alonso G, Santomé L, Afonso FJ: Erlotinib as maintenance therapy after concurrent chemoradiotherapy in patients (p) with stage III non-small cell lung cancer (NSCLC): A Galician Lung Cancer Group phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):7537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: P with unresectable stage IIIA/IIIB-without malignant effusions-NSCLC who had received a standard concurrent chemo-radiotherapy regimen and had no evidence of tumor progression were enrolled in this single arm, open-label phase II study and received erlotinib 150 mg/day po for 6 months.
  • Main eligibility criteria were: PS 0-2, adequate bone marrow, hepatic and renal function and measurable disease by RECIST criteria.
  • Primary endpoint was the percentage of p without evidence of disease progression after 6 months of erlotinib therapy and secondary endpoints were: PFS, OS, ORR and safety profile.
  • Baseline characteristics: median age 62 years (range 41-76); male 94.6%; caucasian 100%; smokers/never smokers (%) 97.3/2.7; ECOG PS 0/1/2 (%) 18.9/75.7/2.7; adenocarcinoma/squamous cell carcinoma/large cell carcinoma (%) 16.2/75.7/5.4; stage IIIA/IIIB (%) 16.2/83.8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963306.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Tanaka F, Yoneda K, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Kondo N, Hasegawa S, Fukuoka K, Nakano T: Circulating tumor cells (CTCs) and endothelial cells (CECs) in primary lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):11066

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11066 Background: Circulating tumor cell (CTC), a surrogate of distant metastasis, and circulating endothelia cell (CEC), a surrogate of angiogenesis, are potentially useful in the diagnosis of malignant tumors, but clinical significance of CTC/CEC in primary lung cancer (LC) remains unclear.
  • In 11 (18.3%) of 145 cases with non-malignant (NM) diseases, CTC was also positive; however, in NM cases, CTC-count was 1 (cell/7.5mL) in most CTC-positive cases and the maximun CTC-count was 2.
  • Among LC cases, the incidence of case with CTC-positive (CTC-count, 1 or more) was highest in small cell carcinoma cases (7/10, 70.0%), followed by squamous cell carcinoma (9/22, 40.9%) and adenocarcinoma (23/94, 24.5%) cases; the incidence of CTC-positive case was significantly higher in stage IV cases (68.6%; p<0.001), but it should be noted that CTC was positive in 17.4% of stage I cases and 15.4% of stage II cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963143.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Calistri D, Rengucci C, Casadei-Gardini A, Scarpi E, Zoli W, Falcini F, Milandri C, Amadori D, Silvestrini R: FL-DNA approach for noninvasive early diagnosis of colorectal cancer in FOBT-screened patients. J Clin Oncol; 2009 May 20;27(15_suppl):11062

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FL-DNA approach for noninvasive early diagnosis of colorectal cancer in FOBT-screened patients.
  • : 11062 Background: A promising approach for the early diagnosis of colorectal cancer (CRC) is the evaluation of genomic DNA integrity (FL-DNA) extracted from stool.
  • Pilot and confirmatory studies carried out by our group have shown that, thanks to its diagnostic accuracy, this molecular assay could be a useful tool for the non-invasive, early diagnosis of CRC.
  • Of the 560 individuals with FOBT-positive stool subjected to colonoscopy, 26 were diagnosed with adenocarcinoma, 264 with high-grade adenoma and 54 with low-grade adenoma.
  • More than one third (216) of the group had only benign disease (hemorrhoids, diverticulitis, inflammation, etc), hyperplastic polyps or nothing.
  • RESULTS: Using a cut-off of 10 ng, the molecular analysis detected over 90% of the colorectal cancers and about 50% of the high- and low-grade adenomas.
  • A more in depth DNA stool evaluation in negative FOBT individuals could reveal the test's usefulness in unmasking colorectal tumors and adenomas missed by FOBT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963138.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Ruhstaller T, Pless M, Schuller JC, Kranzbühler H, von Moos R, Moosmann P, Rauch D, Montemurro M, Schneider PM, Hess V: Cetuximab in combination with chemoradiotherapy prior to surgery in patients with resectable, locally advanced esophageal carcinoma: A prospective, multicenter phase lb-ll trial of the Swiss Group for Clinical Cancer Research (SAKK 75/06). J Clin Oncol; 2009 May 20;27(15_suppl):4570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts with resectable, locally advanced squamous cell carcinoma (SCC) or adenocarcinoma (AC) of the thoracic esophagus or gastroesophageal junction (staged by EUS, CT and PET scan) were treated with 2 cycles of induction chemotherapy (docetaxel 75mg/m2, cisplatin 75mg/m2 q3w and weekly cetuximab 250mg/m2), followed by concomitant chemo- immuno-radiation therapy (CIRT: docetaxel 20mg/m2, cisplatin 25mg/m2 and cetuximab 250mg/m2 weekly five times concomitant with 45 Gy radiotherapy in 25 fractions); followed by surgery 4-8 weeks later.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963079.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Sym S, Park S, Park J, Kwon K, Jung I, Cho E, Lee W, Chung M, Shin D, Lee J: A randomized phase II trial of weekly docetaxel plus either cisplatin or oxaliplatin in patients with previously untreated advanced gastric cancer: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):4566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Chemotherapy-naïve patients with measurable unresectable and/or metastatic gastric adenocarcinoma and a performance status ≤2 were randomly assigned to receive docetaxel (35 mg/m2) weekly on days 1 and 8 of a 21-day cycle plus either cisplatin (60 mg/m2 on day 1) (arm A) or oxaliplatin (120 mg/m2 on day 1) (arm B).
  • Median age was 52 years and disease status was comparable for both arms.
  • No significant difference was noted between the arms both for ORR (p=0.202) or for disease control (58.6% and 82.1%, respectively, p=0.082).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963054.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Cho S, Lee S, Hwang J, Bae W, Shim H, Park C, Park M, Chung I: Phase II study of S-1 monotherapy in taxane, cisplatin refractory gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients were eligible if they had histologically documented gastric adenocarcinoma previously treated with taxane (docetaxel or paclitaxel) and cisplatin; age≥18; Eastern Clinical Oncology Group (ECOG) performance status of 2 or less; adequate organ function; no evidence of gastrointestinal obstruction or passage disturbance.
  • Treatment continued until progression of disease or life-threatening adverse events were occurred.
  • Four (8.3%) patients had a partial response and 18 (37.5%) patients had stable disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963034.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Thuss-Patience PC, Kretzschmar A, Deist T, Hinke A, Bichev D, Lebedinzew B, Schumacher G, Gebauer B, Maier V, Reichardt P: Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol; 2009 May 20;27(15_suppl):4540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eligibility: Metastatic or locally advanced gastro-esophageal junction or gastric adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963017.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Takiuchi H, Nasu J, Nakamura K, Fukuda H, Ohtsu A: Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). J Clin Oncol; 2009 May 20;27(15_suppl):4545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligibility criteria included pts with histologically proven gastric adenocarcinoma; inoperable or recurrent GC; PM with radiologically confirmed intestinal stenosis or ascites; 20-75 years old; PS 0-2; no prior treatment except surgery or adjuvant chemotherapy.
  • Treatment with 5FUci (800mg/m<sup>2</sup>/d, civ, d1-5, q4w) or MF (methotrexate, 100mg/m<sup>2</sup>, iv, followed 3 h later by 5FU, 600mg/m<sup>2</sup>, iv, with leucovorin rescue, q1w) were continued until disease progression or unacceptable toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963012.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. De Vita F, Orditura M, Innocente R, Vecchione L, Pinto C, Chiarion Sileni V, Martinelli E, Ruol A, Catalano G, Ciardiello F: A multicenter phase II study of induction CT with FOLFOX-4 and cetuximab followed by RT and cetuximab in locally advanced esophageal cancer (LAEC). J Clin Oncol; 2009 May 20;27(15_suppl):4546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligibility criteria: resectable, locally advanced (uT3 or uN1, T4 if deemed resectable) squamous cell carcinoma (SCC) or adenocarcinoma (AC) of the esophagus; staged by EUS, CT and PET scan; age 18-70y; PS <2; normal organ functions.All pts received induction treatment with C at a starting dose of 400 mg/m<sup>2</sup> and further weekly infusion at a maintenance dose of 250 mg/m<sup>2</sup> and 4 cycles of FOLFOX-4 every two weeks.
  • The most frequent grade 3/4 toxicity of chemoradiotherapy were skin (32%),neutropenia (29%) and esophagitis (9%); 10 pts had no resection (9 progressive disease,1 patient's refusal).
  • The pathological response rate was 68 %, with a complete histopathological remission recorded in 6 pts (27%);17 pts (53%) are still alive without residual or recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963011.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Kanzler S, Trarbach T, Seufferlein T, Kubicka S, Lordick F, Geissler M, Daum S, Galle PR, Moehler M, German Arbeitsgemeinschaft Internistische Onkologie (AIO): Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients (pts) were eligible with untreated adenocarcinoma of the stomach or oesophagogastric junction, with ECOG performance status (PS) < 2, measurable lesions and adequate organ functions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962992.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Yoon J, Cho S, Bae W, Hwang J, Shim H, Chung I: Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligible criteria were as followed; histologic confirmed adenocarcinoma of stomach, previously treated with taxane and cisplatin, age≥18, Eastern Clinical Oncology Group (ECOG) performance status of 1 or less, adequate organ function.
  • This cycle was repeated every 2 weeks until disease progression or unacceptable toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Hirsch FR, Dziadziuszko R, Varella-Garcia L, Franklin W, Bunn P, Kabbinavar F, Wacker B, Rusk J, Richardson K, Camidge DR: Randomized phase II study of erlotinib (E) or intercalated E with carboplatin/paclitaxel (CP) in chemotherapy-naive advanced NSCLC: Correlation of biomarker status and clinical benefit. J Clin Oncol; 2009 May 20;27(15_suppl):8026

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EGFR-activating mutations were higher among females (19% vs 6% males), adenocarcinoma histology (17% vs 0% others), Asians (45% vs 7% non-Asian), and never smokers (29% vs 7% former and 0% current); KRAS mutations were higher in current smokers (41% vs 27% former and 0% never) and adenocarcinoma histology (22% vs 18% squamous).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962839.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Lind JS, Dingemans AC, Groen HJ, Smit EF: A phase II study of erlotinib and sorafenib in chemotherapy-naive patients with locally advanced/metastatic non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pts received erlotinib (150 mg/od) and sorafenib (400 mg/bd) until disease progression or unacceptable toxicity.
  • RESULTS: 50 pts were enrolled: 22 females; median age 60 yrs (range 41-78); 30 PS 0; 37 stage IV; 34 adenocarcinoma; 11 never smokers; 10/33 EGFR mutations (exons 19 (n=5), 20 (n=1), 21 (n=4)); 3/33 K-Ras mutations.
  • The NPR at 6 weeks was 76%: 13 PR, 25 SD, 8 PD, 4 NE.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962809.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Gandara D, Kim ES, Herbst RS, Moon J, Redman MW, Dakhil SR, Hirsch F, Mack PC, Franklin W, Kelly K: S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):8015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pt characteristics: median age 64 years (42-78), Male/Female 52/52, PS 0/1 43/61, stage IIIB/IV 9/95, adenocarcinoma: 81, current/former smoker: 82.
  • Partial response (PR): 51/95 assessable (54%; 43%-64%); Stable disease (SD): 22/95 (23%).
  • Disease control rate (PR+SD): 77%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962808.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Sharma R, Yang GY, Nava HR, Demmy TL, Nwogu CE, Yendamuri SS, Lamonica D, Tan W, Iyer RV, Khushalani NI: A single institution experience with neoadjuvant chemoradiation (CRT) with irinotecan (I) and cisplatin (C) in locally advanced esophageal carcinoma (LAEC). J Clin Oncol; 2009 May 20;27(15_suppl):e15619

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histology included adenocarcinoma (n=38), squamous cell (n=4), mixed (n=2); 12 PTS had signet-ring cell features.
  • The median disease-free and overall survival is 24 months and 34 months, respectively; 3-yr overall survival is 46%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962730.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Jhawer M, Kindler HL, Wainberg Z, Ford J, Kunz P, Tang L, McCallum S, Kallender H, Shah MA, MET111643 Investigators and GlaxoSmithKline: Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts with distal esophagus, GE junction or stomach adenocarcinoma, 0-2 prior chemotherapy regimens, adequate organ function, measurable disease, and ECOG PS 0-2 are sequentially enrolled in 2 cohorts:.
  • Best response of stable disease (SD), was noted in 6/41 (15%) pts in the 5 on/9 off cohort (none were cMET-amplified), with 2 pts SD >6 months, 1 ongoing; and in 3/14 (21%) pts in the daily cohort.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962690.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Gralla RJ, Hollen PJ, Thongprassert S, Kim H, Yuankai S, Hsia T, Wu C, Park K, Liu T, Asia-Pacific QL Trial Group: Using health-related quality of life (QL) parameters as primary endpoints in a multinational prospective NSCLC chemotherapy (chemo) trial: The Asia-Pacific QL trial. J Clin Oncol; 2009 May 20;27(15_suppl):8086

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) evaluate the impact of chemo on QL and symptoms for all pts, 2) evaluate QL by response category (CR+PR = MR or major response, stable disease = SD, and progression); and 3) test whether barriers in QL evaluation are overcome by using a computer-assisted validated instrument (LCSS-QL).
  • Demographics: 77% Stage IV; 72% men; 67% adenocarcinoma; median age 58; KPS 90-100 = 66%, 70-80 = 34%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962663.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Edelman MJ, Belani CP, Socinski MA, Ansari R, Obasaju CK, Monberg MJ, Chen R, Treat J: Incidence and outcomes associated with brain metastases (BM) in a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8076

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Analyses of pts with lung cancer from the 1970s and 1980s indicated that the incidence of BM at the time of diagnosis was approximately 10%.
  • Cycles were repeated every 21 d up to 6 cycles or disease progression.
  • 1) The higher incidence of BM (17.1%) observed in this trial may be related to the increasing incidence of adenocarcinoma, or to the increasing sensitivity of imaging modalities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962650.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Karp DD, Novello S, Cardenal F, Haluska P, Blakely LJ, Garland L, Paz-Ares LG, Dolled-Filhart MP, Johnson ED, Gualberto A: Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):8072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Fifty-six pts with non-adenocarcinoma NSCLC were enrolled.
  • Pts received T (200 mg/m2), C (AUC of 6) and F (20 mg/kg) q3weeks for up to 6 cycles; pts with response (PR) or stable disease were eligible to continue F as single agent until disease progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962646.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Cobo M, Martinez J, Montesa A, Gil-Calle S, Villar-Chamorro E, Ales I, Gutierrez V, Durán G, Carabantes-Ocón F, Benavides M: Phase II trial of erlotinib maintenance therapy after platinun-based chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HISTOLOGY: adenocarcinoma 8(61.7%), bronquioloalveolar 3(6.4%), large cell 3(6.4%), squamous12(25.5%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962630.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Belvedere O, Follador A, Rossetto C, Sibau AM, Defferrari C, Aita M, Meduri S, Fasola G, Ceschia T, Grossi F: Final report of a randomized phase II study of docetaxel/oxaliplatin (DO) and docetaxel (D) in previously treated non-small cell lung cancer (NSCLC) patients (pts). A novel design, Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 019). J Clin Oncol; 2009 May 20;27(15_suppl):e19010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pts characteristics: M/F, 76/24%; median age 62 yrs (range 43-69); ECOG PS 0/1, 36/64%; adenocarcinoma/other, 36/64%.
  • With 48 pts evaluable, partial response was seen in 20% and 8% of pts; stable disease in 52% and 32% and progressive disease in 24% and 56% for DO and D, respectively; 1 pt was inevaluable due to early death (D arm).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962629.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Ferrer N, Cobo M, Paredes A, Méndez M, Muñoz-Langa J, Rueda A, Álvarez de Mon M, Sánchez-Hernández A, Gallego R, Torrego J: Phase II study of bevacizumab in combination with cisplatin and docetaxel as first-line treatment of patients (p) with metastatic non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19023

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • P received D (75 mg/m<sup>2</sup>), C (75 mg/m<sup>2</sup>), and B (15 mg/kg iv) on day 1 every 3 weeks for up to 6 cycles, followed by B 15 mg/kg alone every 3 weeks until disease progression or toxicity.
  • RESULTS: 50 p were enrolled (enrollment completed): 24% female, median age 60 (36-74), PS 1: 64%, adenocarcinoma: 72%; stage IV: 92%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962586.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Lee S, Ryoo H, Bae S, Song H, Kim M, Lee K, Lee W, Park K, Kim J, Baek J: Fixed dose rate infusion of gemcitabine and UFT combination chemotherapy in patients with advanced biliary cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We included the chemo-naive patients with measurable metastatic or recurrent biliary adenocarcinoma except gall bladder cancer.
  • Partial response was 24.2% and disease control rate was 51.5%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962362.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Moon Y, Rha S, Jeung H, Shin S, Yoo N, Roh J, Noh S, Chung H: Clinical outcome of sequential chemotherapy in metastatic and/or recurrent gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to analyze the natural history of stage IV gastric cancer with sequential CTx Methods: A total of 532 patients (pts) with unresectable gastric adenocarcinoma were studied.
  • Response of unmeasurable lesions was dichotomized only into stable disease or progressive disease.
  • Median overall survivals from diagnosis of unresectable cancer were 12.0/13.3/2.5 months for overall/CTx/BSC, respectively.
  • Response and disease control rates were 21.7%/12.5%/11.8% and 79.4%/56.3%/49.4% for 1<sup>st</sup>/2<sup>nd</sup>/3<sup>rd</sup> lines, respectively.
  • The most common cause of discontinuation of CTx was disease progression (68%/74%/70%) followed by pt's refusal (22%/13%/12%) for 1<sup>st</sup>/2<sup>nd</sup>/3<sup>rd</sup> lines, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962260.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Uronis HE, Bullock K, Blobe G, Hsu S, Morse M, Nixon A, Haley S, O'Neill M, Hurwitz H, Bendell J: A phase I study of gemcitabine plus dasatinib (GD) or gemcitabine plus dasatinib plus cetuximab (GDC) in refractory solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: 25 pts have been enrolled, including 21 with pancreatic adenocarcinoma, 3 of whom had received prior G. 21 pts were evaluable for toxicity and 18 for efficacy.
  • Eight of 18 pts, 3 of whom had received prior G, had stable disease as best response, median duration = 5 months (range 1-7).
  • Stable disease in previous G-refractory pts was noted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962236.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Shenglin M, Yaping X, Xinmin Y, Yang Y: Multidisciplinary management of brain metastases from non-small cell lung cancer: A retrospective study of 251 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e19030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Variables analyzed included the recursive partitioning analysis (RPA) grouping, weight loss, LDH in blood serum, sex, age, time of brain metastasis (synchronous vs. metachronous), number of brain metastases, maximum diameter of largest brain lesion, Karnofsky performance status, histologic type (adenocarcinoma vs. other types of NSCLC), TNM stage (without consideration of brain involvement), and the treatment modality used for both the primary NSCLC tumor and brain metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962119.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ardavanis A, Baxevanis CN, Rigatos G, Papamichail M, Perez SA: A phase I trial of adoptive transfer of allogeneic natural killer (NK) cells in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):3001

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Between 11/2007 and 11/2008 16 pts (performance status 0-1) were enrolled; 1 pt had rapid disease progression before treatment.
  • Pts characteristics: M/F 12/4; histology: adenocarcinoma/squamous cell carcinoma 13/3; stage IIIb/IV 2/14; 1<sup>st</sup>/2<sup>nd</sup> line treatment 13/3; median age 64 years (range, 50-71).
  • With a median follow-up of 6 months (range, 1-14) 3 pts with partial response and 7 pts with disease stabilization were recorded.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962051.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Kim K, Jang GD, Lim HS, Kim HS, Shin JG, Lee JL, Ryu MH, Chang HM, Kang YK, Kim TW: Pharmacokinetic and pharmacogenetic study of S-1 in Korean patients with metastatic biliary cancer. J Clin Oncol; 2009 May 20;27(15_suppl):2505

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: This is a prospective study of patients with histologically confirmed metastatic adenocarcinoma of the biliary tract.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961956.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Walker M, Peltz G, Houts A, Pohl G, Schwartzberg L, Stepanski E, Marciniak M: Psychosocial impact of cancer-related symptoms among patients with lung cancer. J Clin Oncol; 2009 May 20;27(15_suppl):6621

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stage of disease was 19% stage IV, 22% stage I-III, and 59% unspecified.
  • Histological type was 36% adenocarcinoma, 18% squamous cell, 37% unspecified, and 9% other.
  • The most common comorbidities were anemia, other malignancies, and respiratory disease.
  • Depressive disorder was recorded for < 5% of patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Lujan M, Cardona AF, Yepes A, Carrasco-Chaumel E, Reveiz L, Otero JM: Myelophthisis in solid tumors: Old aspects, new concepts (ONCOLGroup study). J Clin Oncol; 2009 May 20;27(15_suppl):e20672

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-seven pts (30%) had breast cancer, pathology followed by primary unknown tumours (21%), rabdomiosarcoma (10%), prostate adenocarcinoma (10%), gastric carcinoma (7%) and others (22%).
  • Forty-three pts received chemotherapy following the diagnosis of medullar infiltration, and normal leukocyte count was being seen in 40% of them after such treatment.
  • Nine episodes of febrile neutropenia were found; median overall survival (OS) following the diagnosis of neoplasia and myelophtisis were 13.8 months and 2.2 months respectively.
  • The factors related to lower survival rate were the presence of Hb ≤8.5 gr/dl (HR: 0,54, CI95% 0,32-0,95; p = 0.04), >3 metastasis sites (HR: 0,67, CI95% 0,45-0,92; p = 0.03), visceral disease (HR: 0,72, CI95% 0,66-0,89; p = 0.04) and febrile neutropenia caused by chemotherapy (HR: 0,52, CI95% 0,37-0,60; p = 0.02).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Chang VT, Hoover DR, Cogswell J, Cholankeril M, Badin S, Yang W, Yan H, Gonzalez ML, Einhorn J, Kasimis BS: Comorbidity and survival in advanced non-small cell lung cancer (NSCLC) veteran patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20675

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20675 Background: Prognostic value of comorbidity at diagnosis has received increasing attention.
  • Histologies were adenocarcinoma in 48 (48%) pts, squamous cell in 37 (37%) pts, and other 17 (15%) pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961684.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Scheusan R, Curescu S, Stanculeanu D, Curescu P: Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metronomic chemotherapy, chronic administration of chemotherapy at relatively low, minimally toxic doses on a frequent schedule with no prolonged drug-free breaks, is a potentially novel approach to the control of advanced cancer disease.
  • METHODS: From May 2007 to July 2008, 11 patients with refractory pretreated ovarian adenocarcinoma were included.
  • Patient's characteristics: median age 51 years (range 41-64), ECOG 0-2, progression after more than two lines of chemotherapy for recurrent disease.
  • TREATMENT: low-dose oral methotrexate 2.5 mg bd on days 1 and 2 each week and cyclophosphamide 50 mg/day administered continuously until disease progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961511.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Lord SR, Vasudev N, Knight S, Speirs V, Hall G: Prognostic significance of immunohistochemical markers in endometrial cancer treated with chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e16551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The commonest histological subtypes were endometrioid adenocarcinoma (40%), serous carcinoma (24.1%) and mixed mullerian tumours (14.6%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960814.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Bondi J, Pretorius M, Bukholm I, Danielsen H: Large-scale genomic instability in colon adenocarcinomas and correlation with patient outcome. APMIS; 2009 Oct;117(10):730-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large-scale genomic instability in colon adenocarcinomas and correlation with patient outcome.
  • The purpose of this study was to evaluate the association between DNA content in colon adenocarcinomas using high-resolution image cytometry and patient outcome.
  • Tumours from 219 patients operated for colon adenocarcinoma were analysed using high-resolution image cytometry.
  • The results were related to disease-free survival and to cancer-specific death.
  • DNA content in colon adenocarcinomas measured by image cytometry is an independent predictor of prognosis in our patients operated for colon adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Neoplasms / genetics. Genomic Instability
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Ploidies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19775341.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


78. Veras E, Srodon M, Neijstrom ES, Ronnett BM: Metastatic HPV-related cervical adenocarcinomas presenting with thromboembolic events (Trousseau Syndrome): clinicopathologic characteristics of 2 cases. Int J Gynecol Pathol; 2009 Mar;28(2):134-9
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic HPV-related cervical adenocarcinomas presenting with thromboembolic events (Trousseau Syndrome): clinicopathologic characteristics of 2 cases.
  • Two cases of systemic thromboembolism (Trousseau syndrome) associated with metastatic human papillomavirus (HPV)-related endocervical adenocarcinomas are reported.
  • Lymph node biopsy revealed metastatic mucinous adenocarcinoma with focal signet ring cell differentiation.
  • Imaging studies demonstrated metastatic disease without a defined primary site.
  • Autopsy examination revealed widespread metastatic adenocarcinoma with a 2 cm cervical adenocarcinoma.
  • Diagnostic laparoscopy with biopsies and left oophorectomy revealed metastatic mucinous adenocarcinoma with signet ring cell differentiation involving peritoneum, ovary, cervix, and bladder without a defined primary site.
  • Progressive thromboembolic disease with acute renal failure and multiple cerebral infarcts developed and the patient expired shortly after initiation of chemotherapy, 2 months after presentation.
  • High-risk HPV-related endocervical adenocarcinomas occasionally exhibit signet ring cell differentiation and can present with Trousseau syndrome.
  • These features more commonly suggest metastatic adenocarcinoma of upper gastrointestinal tract origin but the presence of HPV DNA within the tumors establishes them as cervical in origin.
  • [MeSH-major] Adenocarcinoma / complications. Papillomavirus Infections / complications. Thromboembolism / etiology. Uterine Cervical Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188822.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Maddocks OD, Short AJ, Donnenberg MS, Bader S, Harrison DJ: Attaching and effacing Escherichia coli downregulate DNA mismatch repair protein in vitro and are associated with colorectal adenocarcinomas in humans. PLoS One; 2009;4(5):e5517
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attaching and effacing Escherichia coli downregulate DNA mismatch repair protein in vitro and are associated with colorectal adenocarcinomas in humans.
  • BACKGROUND: Mucosa-associated Escherichia coli are frequently found in the colonic mucosa of patients with colorectal adenocarcinoma, but rarely in healthy controls.
  • Adenocarcinoma and normal colonic mucosa from colorectal cancer patients (n = 20) was probed by immunofluorescence and PCR for AEEC.
  • Mucosa-associated E. coli were found on 10/20 (50%) adenocarcinomas and 3/20 (15%) normal mucosa samples (P<0.05).
  • AEEC were detected on 5/20 (25%) adenocarcinomas, but not normal mucosa samples (P<0.05).

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Infect Immun. 2001 May;69(5):3315-22 [11292754.001]
  • [Cites] J Clin Invest. 2001 Mar;107(5):621-9 [11238563.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15107-12 [11742074.001]
  • [Cites] Cell Microbiol. 2002 Apr;4(4):235-43 [11952640.001]
  • [Cites] Mutat Res. 2002 Jun;511(2):145-78 [12052432.001]
  • [Cites] J Immunol Methods. 2002 Jul 1;265(1-2):39-47 [12072177.001]
  • [Cites] Gastroenterology. 2002 Aug;123(2):542-53 [12145807.001]
  • [Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]
  • [Cites] Environ Mol Mutagen. 2002;40(4):243-50 [12489114.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):217-24 [12584170.001]
  • [Cites] DNA Repair (Amst). 2003 May 13;2(5):571-80 [12713814.001]
  • [Cites] J Clin Microbiol. 2003 Jun;41(6):2289-93 [12791838.001]
  • [Cites] Infect Immun. 2003 Jul;71(7):3995-4002 [12819087.001]
  • [Cites] Clin Microbiol Rev. 2003 Jul;16(3):365-78 [12857773.001]
  • [Cites] Microbes Infect. 2004 Jan;6(1):38-50 [14738892.001]
  • [Cites] Microbiology. 2004 Mar;150(Pt 3):527-38 [14993302.001]
  • [Cites] FEBS Lett. 2004 Mar 26;562(1-3):40-4 [15043999.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):20127-36 [14988394.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):80-93 [15236175.001]
  • [Cites] Nucleic Acids Res. 2004;32(12):e100 [15249596.001]
  • [Cites] Cell Microbiol. 2004 Nov;6(11):1097-111 [15469437.001]
  • [Cites] Annu Rev Cell Dev Biol. 2004;20:695-723 [15473857.001]
  • [Cites] J Med Microbiol. 2004 Nov;53(Pt 11):1137-44 [15496393.001]
  • [Cites] Emerg Infect Dis. 2004 Oct;10(10):1797-805 [15504266.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):769-80 [15510158.001]
  • [Cites] J Clin Invest. 1969 Aug;48(8):1423-32 [5796354.001]
  • [Cites] J Biol Chem. 1973 Apr 10;248(7):2542-8 [4698231.001]
  • [Cites] J Cell Biol. 1974 Aug;62(2):329-43 [4609988.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1259-64 [8577751.001]
  • [Cites] Infect Immun. 1996 Mar;64(3):966-73 [8641808.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):808-11 [9041175.001]
  • [Cites] Infect Immun. 1997 Jul;65(7):2528-36 [9199415.001]
  • [Cites] Infect Immun. 1997 Aug;65(8):3277-85 [9234787.001]
  • [Cites] Clin Microbiol Rev. 1998 Jan;11(1):142-201 [9457432.001]
  • [Cites] Infect Immun. 1998 Apr;66(4):1570-8 [9529083.001]
  • [Cites] Mutat Res. 1998 Feb 26;398(1-2):93-9 [9626969.001]
  • [Cites] Gastroenterology. 1998 Aug;115(2):281-6 [9679033.001]
  • [Cites] J Biol Chem. 1998 Sep 25;273(39):25436-42 [9738012.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3911-5 [10097137.001]
  • [Cites] Mutat Res. 1999 Jun 30;427(2):67-78 [10393261.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):137-47 [15619620.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] Infect Immun. 2006 Sep;74(9):5419-21 [16926439.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9036-44 [16982745.001]
  • [Cites] Curr Opin Microbiol. 2007 Feb;10(1):76-81 [17208515.001]
  • [Cites] Mol Cancer Res. 2007 Feb;5(2):165-70 [17293392.001]
  • [Cites] Cell Microbiol. 2007 May;9(5):1352-64 [17474908.001]
  • [Cites] Cancer Res. 1977 Dec;37(12):4352-60 [922726.001]
  • [Cites] Infect Immun. 1983 Sep;41(3):1340-51 [6350186.001]
  • [Cites] Epidemiol Rev. 1984;6:31-51 [6386503.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2405-14 [3886132.001]
  • [Cites] Infect Immun. 1987 Jan;55(1):69-77 [3539808.001]
  • [Cites] Cancer Res. 1988 Apr 1;48(7):1936-42 [3349466.001]
  • [Cites] Infect Immun. 1993 Jan;61(1):350-5 [8418061.001]
  • [Cites] J Bacteriol. 1993 Aug;175(15):4670-80 [8393004.001]
  • [Cites] Nat Genet. 1995 Jan;9(1):48-55 [7704024.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] J Clin Microbiol. 1995 Aug;33(8):2064-8 [7559949.001]
  • [Cites] Science. 2000 Feb 25;287(5457):1497-500 [10688800.001]
  • [Cites] J Infect Dis. 2000 Apr;181(4):1496-500 [10762584.001]
  • [Cites] J Biol Chem. 1971 Sep 10;246(17):5466-76 [10970180.001]
  • [Cites] J Infect Dis. 2001 Jul 15;184(2):227-30 [11424022.001]
  • (PMID = 19436735.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA141038; United Kingdom / Cancer Research UK / / 617SUR R40245; United Kingdom / Cancer Research UK / / C505/A7328; United Kingdom / Medical Research Council / / MRCDTGG122/5
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins
  • [Other-IDs] NLM/ PMC2677459
  •  go-up   go-down


80. Georgel T, Jankowski R, Henrot P, Baumann C, Kacha S, Grignon B, Toussaint B, Graff P, Kaminsky MC, Geoffrois L, Vignaud JM: CT assessment of woodworkers' nasal adenocarcinomas confirms the origin in the olfactory cleft. AJNR Am J Neuroradiol; 2009 Aug;30(7):1440-4
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT assessment of woodworkers' nasal adenocarcinomas confirms the origin in the olfactory cleft.
  • BACKGROUND AND PURPOSE: Endoscopic endonasal surgery let us observe that woodworkers' nasal adenocarcinomas originate in the olfactory cleft.
  • Our aim was the identification of CT imaging features that corroborate the olfactory cleft as the site of origin for woodworkers' adenocarcinoma.
  • MATERIALS AND METHODS: We designed a retrospective study to compare CT scans of 27 unilateral olfactory cleft adenocarcinomas with 30 cases of nasosinusal polyposis (NSP) and 33 healthy sinus controls.
  • RESULTS: The nasal septum was significantly bulging across the midline in adenocarcinoma (4.6 +/- 3 mm; range, -0.1-13.7 mm) compared with NSP (0.7 +/- 1 mm; range, -2.1-2.3 mm) or healthy sinus controls (0.5 +/- 1 mm; range, -1.2-2 mm) (P < .001).
  • The olfactory cleft was significantly wider in adenocarcinoma (15.1 +/- 4.5 mm; range, 8.6-25.7 mm) than in NSP (3.6 +/- 0.4 mm; range, 2.8-4.6 mm) or healthy sinus controls (3.3 +/- 0.7 mm; range, 1.4-4.6 mm).
  • The ethmoidal labyrinth width was significantly smaller on the pathologic side in adenocarcinoma (7.2 +/- 2.7 mm; range, 3.2-14.2 mm) than in the control groups (P < .001).
  • Whereas the angle between the conchal lamina and vertical midline was close to zero degrees in NSP (0.03 +/- 2.25 degrees ; range, -5 degrees -3 degrees ) and healthy sinus controls (0.45 +/- 2.13 degrees , range, -5 degrees -5 degrees ), it reached 39.76 +/- 13.83 degrees (P < .001) in adenocarcinoma.
  • CONCLUSIONS: Radiologists should suspect nasal adenocarcinoma on sinus CT scans showing a unilateral expanding opacity of the olfactory cavity.
  • [MeSH-major] Adenocarcinoma / radiography. Nasal Cavity / radiography. Nose Neoplasms / radiography. Occupational Diseases / radiography. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19541776.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Inamura K, Togashi Y, Okui M, Ninomiya H, Hiramatsu M, Satoh Y, Okumura S, Nakagawa K, Shimoji T, Noda T, Ishikawa Y: HOXB2 as a novel prognostic indicator for stage I lung adenocarcinomas. J Thorac Oncol; 2007 Sep;2(9):802-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HOXB2 as a novel prognostic indicator for stage I lung adenocarcinomas.
  • BACKGROUND: Outcomes of patients with lung adenocarcinomas can be predicted to some extent from the pathologic stage (p-stage).
  • Although all attempts are made to fully remove cancer lesions, still a number of p-stage I patients without metastatic disease at the time of surgery develop recurrences and die of cancer.
  • Using real-time reverse-transcriptase polymerase chain reaction analysis, we investigated the transcriptional levels of the top metastasis-related genes using 96 independent test lung adenocarcinoma samples and investigated their correlations with the prognosis.
  • [MeSH-major] Adenocarcinoma. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Lung Neoplasms. RNA, Neoplasm / genetics. Transcription Factors / genetics
  • [MeSH-minor] Cell Differentiation. Cell Line, Tumor. Female. Humans. Male. Neoplasm Staging. Nuclear Proteins. Prognosis. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Oncol. 2008 Jan;3(1):100. Ishikawa, Yuichi [added]
  • (PMID = 17805056.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HOXB2 protein, human; 0 / Homeodomain Proteins; 0 / Nuclear Proteins; 0 / RNA, Neoplasm; 0 / Transcription Factors
  •  go-up   go-down


82. Langer R, Mutze K, Becker K, Feith M, Ott K, Höfler H, Keller G: Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study. J Clin Pathol; 2010 Nov;63(11):994-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study.
  • AIMS: To investigate the expression of class I histone deacetylase (HDAC) isoforms 1 and 2 in oesophageal adenocarcinomas.
  • CONCLUSIONS: High HDAC2 expression is associated with aggressive tumour behaviour in oesophageal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Esophageal Neoplasms / metabolism. Histone Deacetylase 1 / metabolism. Histone Deacetylase 2 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Esophagectomy. Female. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Prognosis. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20924032.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 3.5.1.98 / HDAC1 protein, human; EC 3.5.1.98 / HDAC2 protein, human; EC 3.5.1.98 / Histone Deacetylase 1; EC 3.5.1.98 / Histone Deacetylase 2
  •  go-up   go-down


83. Ridgway PF, Ziprin P, Alkhamesi N, Paraskeva PA, Peck DH, Darzi AW: Hypoxia augments gelatinase activity in a variety of adenocarcinomas in vitro. J Surg Res; 2005 Apr;124(2):180-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypoxia augments gelatinase activity in a variety of adenocarcinomas in vitro.
  • BACKGROUND: Hypoxia within solid adenocarcinomas and protease up-regulation has been independently implicated as poor prognostic indicators in a variety of tumor types.
  • This suggests a mechanism explaining the poorer prognosis seen in patients with protease-secreting solid adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Anoxia / metabolism. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Pancreatic Neoplasms / metabolism
  • [MeSH-minor] Breast Neoplasms. Cell Line, Tumor. Cell Survival. Colonic Neoplasms. Enzyme Inhibitors / pharmacology. Humans. In Vitro Techniques. Matrix Metalloproteinase Inhibitors. Neoplasm Invasiveness. Tissue Inhibitor of Metalloproteinase-1 / metabolism. Up-Regulation

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820246.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Matrix Metalloproteinase Inhibitors; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


84. Park SY, Lee HS, Choe G, Chung JH, Kim WH: Clinicopathological characteristics, microsatellite instability, and expression of mucin core proteins and p53 in colorectal mucinous adenocarcinomas in relation to location. Virchows Arch; 2006 Jul;449(1):40-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics, microsatellite instability, and expression of mucin core proteins and p53 in colorectal mucinous adenocarcinomas in relation to location.
  • However, there have been few studies of mucinous adenocarcinoma (MA) in relation to location.
  • Ninety-six consecutive colorectal MAs and ninety-eight nonmucinous adenocarcinomas (nMAs) were investigated.
  • Right-sided MAs, by comparison with those on the left side, were characterized by older age, larger tumor size, lower stage at presentation, peritumoral lymphocytic response, background of serrated adenoma, MSI-H phenotype, higher MUC2 and MUC5AC expression, and lower p53 protein overexpression.
  • In univariate analysis, right-sided location had a favorable effect on disease specific survival of the patients with MA, although it is not an independent predictor of survival.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Chromosomal Instability / genetics. Colorectal Neoplasms / genetics. Mucins / biosynthesis. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Glycoconj J. 1996 Oct;13(5):693-707 [8909996.001]
  • [Cites] Hum Pathol. 1999 Jun;30(6):629-34 [10374769.001]
  • [Cites] J Histochem Cytochem. 1999 Aug;47(8):1039-48 [10424888.001]
  • [Cites] Gastroenterology. 1994 Feb;106(2):353-61 [7905449.001]
  • [Cites] J Pathol. 2001 Oct;195(3):327-35 [11673830.001]
  • [Cites] Am J Pathol. 1994 Jul;145(1):148-56 [8030745.001]
  • [Cites] Gut. 1998 May;42(5):673-9 [9659163.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2107-16 [11733361.001]
  • [Cites] Mod Pathol. 2004 Jun;17 (6):696-700 [15017435.001]
  • [Cites] J Pathol. 1999 Apr;187(5):499-502 [10398112.001]
  • [Cites] Science. 1993 May 7;260(5109):812-6 [8484121.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):563-70 [12717242.001]
  • [Cites] Science. 1993 May 7;260(5109):816-9 [8484122.001]
  • [Cites] J Pathol. 2001 Mar;193(3):286-94 [11241406.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4017-25 [11051251.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cancer. 2005 May 15;103(10 ):2023-9 [15812832.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10 (3):972-80 [14871975.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):755-62 [12917207.001]
  • [Cites] Cancer Lett. 1996 Jun 5;103(2):163-70 [8635153.001]
  • [Cites] Dig Dis. 1997 Jul-Oct;15(4-5):302-11 [9359018.001]
  • [Cites] Pathol Int. 2002 Jul;52(7):470-7 [12167106.001]
  • [Cites] J Gastroenterol. 2004;39(2):125-32 [15069618.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jun;127(6):694-700 [12741892.001]
  • [Cites] Lancet. 1987 Jun 6;1(8545):1303-6 [2884421.001]
  • [Cites] Pathol Res Pract. 2004;200(5):371-7 [15239345.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2790-6 [15102686.001]
  • [Cites] Cancer. 1976 Apr;37(4):1891-1900 [177180.001]
  • [Cites] Virchows Arch. 1995;426(3):223-7 [7773500.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Am J Surg. 1993 Sep;166(3):257-61 [8396358.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Jan;11(1):77-81 [8672747.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1909-16 [10815915.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):643-8 [11807791.001]
  • (PMID = 16645863.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucins; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


85. Johnson SK, Haun RS: The gamma-aminobutyric acid A receptor pi subunit is overexpressed in pancreatic adenocarcinomas. JOP; 2005 Mar;6(2):136-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The gamma-aminobutyric acid A receptor pi subunit is overexpressed in pancreatic adenocarcinomas.
  • SETTING: Five pancreatic ductal adenocarcinomas and 5 bulk pancreatic ducts isolated from independent pancreatic specimens without malignancies were analyzed by differential display.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Pancreatic Ductal / genetics. Gene Expression Regulation, Neoplastic. Protein Subunits / genetics. Receptors, GABA-A / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Proliferation. DNA, Complementary. DNA, Neoplasm / analysis. DNA, Neoplasm / genetics. Gene Expression Profiling. Humans. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology. RNA, Messenger / analysis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Guide to Pharmacology. gene/protein/disease-specific - GABAA receptor pi subunit - data and references .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767729.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Complementary; 0 / DNA, Neoplasm; 0 / Protein Subunits; 0 / RNA, Messenger; 0 / Receptors, GABA-A
  •  go-up   go-down


86. Bastide K, Ugolin N, Levalois C, Bernaudin JF, Chevillard S: Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level? Lung Cancer; 2010 Apr;68(1):1-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level?
  • Adenocarcinomas (AC), squamous cell carcinomas (SCC) and adenosquamous carcinomas (ASC) are three histological subtypes of non-small-cell lung carcinomas (NSCLC).
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Adenosquamous / genetics. Carcinoma, Squamous Cell / genetics. Lung / metabolism. Lung Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. RADON, RADIOACTIVE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20004040.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / GATA6 Transcription Factor; 0 / Gata6 protein, rat; 0 / Mucin-1; 0 / Receptor, Notch2; Q74S4N8N1G / Radon
  • [Number-of-references] 61
  •  go-up   go-down


87. Tang M, Asamoto M, Ogawa K, Naiki-Ito A, Sato S, Takahashi S, Shirai T: Induction of apoptosis in the LNCaP human prostate carcinoma cell line and prostate adenocarcinomas of SV40T antigen transgenic rats by the Bowman-Birk inhibitor. Pathol Int; 2009 Nov;59(11):790-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of apoptosis in the LNCaP human prostate carcinoma cell line and prostate adenocarcinomas of SV40T antigen transgenic rats by the Bowman-Birk inhibitor.
  • The present study was undertaken to evaluate the effects of BBI on androgen-sensitive/dependent prostate cancers using a human prostate cancer cell (LNCaP) and the transgenic rats developing adenocarcinoma of the prostate (TRAP) model.
  • Feeding of 3% roughly prepared BBI (BBIC) to TRAP from the age 3 weeks to 13 weeks resulted in significant reduction of the relative epithelial areas within the acinus and multiplicity of the adenocarcinomas in the lateral prostate lobes.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Prostatic Neoplasms / drug therapy. Trypsin Inhibitor, Bowman-Birk Soybean / pharmacology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19883429.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Connexin 43; 0 / Trypsin Inhibitor, Bowman-Birk Soybean
  •  go-up   go-down


88. Lee JH, Kim JH, Choi JW, Kim YS: The presence of a micropapillary component predicts aggressive behaviour in early and advanced gastric adenocarcinomas. Pathology; 2010;42(6):560-3
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The presence of a micropapillary component predicts aggressive behaviour in early and advanced gastric adenocarcinomas.
  • However, little is known about the clinicopathological significance of the MC in gastric adenocarcinoma.
  • METHODS: We investigated the clinicopathological characteristics of gastric adenocarcinoma with a MC and compared them with those of conventional gastric adenocarcinoma.
  • The presence of a MC in gastric adenocarcinoma was significantly associated with the depth of invasion, lymph node metastasis, lymphovascular invasion, perineural invasion, higher clinical stages, and poor overall survival rates, but not with age, gender, tumour size, location, and Lauren histological types.
  • CONCLUSIONS: Recognition of a MC in early and advanced gastric adenocarcinomas is very important as it can predict cancer invasion and metastasis leading to a poor clinical outcome.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasm Invasiveness / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20854075.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


89. Sales KJ, List T, Boddy SC, Williams AR, Anderson RA, Naor Z, Jabbour HN: A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas. Cancer Res; 2005 Sep 01;65(17):7707-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas.
  • In the present study, we found elevated FP receptor and vascular endothelial growth factor (VEGF) expression colocalized in glandular epithelial and vascular cells lining the blood vessels in endometrial adenocarcinomas.
  • We investigated the signaling pathways activated by the FP receptor and their role in modulating VEGF expression in endometrial adenocarcinoma (Ishikawa) cells.
  • Finally, we confirmed that PGF2alpha could potentiate angiogenesis in endometrial adenocarcinoma explants by transactivation of the EGFR and induction of VEGF mRNA expression.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / metabolism. Dinoprost / metabolism. Endometrial Neoplasms / blood supply. Endometrial Neoplasms / metabolism. MAP Kinase Signaling System / physiology. Receptors, Prostaglandin / metabolism

  • Hazardous Substances Data Bank. PROSTAGLANDIN F2ALPHA .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Obstet Gynaecol. 1988 Feb;95(2):162-5 [2894838.001]
  • [Cites] J Pharmacol Exp Ther. 1999 Sep;290(3):1278-84 [10454504.001]
  • [Cites] Prostaglandins. 1993 May;45(5):413-26 [8321911.001]
  • [Cites] Int J Cancer. 1994 Jan 2;56(1):26-30 [8262674.001]
  • [Cites] J Biol Chem. 1994 Jan 28;269(4):2632-6 [8300593.001]
  • [Cites] Mol Pharmacol. 1994 Sep;46(3):477-84 [7935328.001]
  • [Cites] Hum Pathol. 1995 Aug;26(8):892-6 [7635451.001]
  • [Cites] Nature. 1996 Feb 8;379(6565):557-60 [8596637.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):454-60 [8697391.001]
  • [Cites] EXS. 1997;79:1-8 [9002217.001]
  • [Cites] J Biol Chem. 1998 Mar 20;273(12):6689-97 [9506966.001]
  • [Cites] Adv Cancer Res. 1998;74:49-139 [9561267.001]
  • [Cites] Mol Endocrinol. 1998 Jun;12(6):815-24 [9626657.001]
  • [Cites] Cell. 1998 May 29;93(5):705-16 [9630216.001]
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] Am J Orthop (Belle Mead NJ). 1999 Mar;28(3 Suppl):8-12 [10193997.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):177-83 [10209148.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Jun;31(6):637-43 [10404636.001]
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9572-80 [10734107.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1024-8 [10973323.001]
  • [Cites] Trends Endocrinol Metab. 2000 Apr;11(3):91-9 [10707049.001]
  • [Cites] Oncogene. 2001 Mar 26;20(13):1540-6 [11313900.001]
  • [Cites] J Clin Endocrinol Metab. 2001 May;86(5):2243-9 [11344234.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4143-54 [11358838.001]
  • [Cites] J Biol Chem. 2001 Feb 16;276(7):4554-63 [11083862.001]
  • [Cites] J Clin Invest. 2001 Jul;108(1):25-30 [11435452.001]
  • [Cites] Nat Med. 2001 Sep;7(9):1048-51 [11533709.001]
  • [Cites] Br J Cancer. 2001 Sep 28;85(7):1023-31 [11592775.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):424-32 [11809691.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):506-11 [11809702.001]
  • [Cites] Endocrinology. 2002 Mar;143(3):1018-25 [11861527.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31 [12242329.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3592-600 [12429651.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5669-73 [14522881.001]
  • [Cites] J Clin Invest. 2003 Oct;112(8):1134-6 [14561696.001]
  • [Cites] Reproduction. 2003 Nov;126(5):559-67 [14611628.001]
  • [Cites] Exp Cell Res. 2004 Jan 1;292(1):201-8 [14720519.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):986-93 [14764825.001]
  • [Cites] Endocrinology. 2004 May;145(5):2228-44 [14736735.001]
  • [Cites] Mol Endocrinol. 2004 Jun;18(6):1533-45 [15044590.001]
  • [Cites] Am J Obstet Gynecol. 1978 Mar 15;130(6):640-6 [637076.001]
  • [Cites] Br J Obstet Gynaecol. 1981 Apr;88(4):434-42 [7225303.001]
  • [Cites] J Clin Endocrinol Metab. 1983 Aug;57(2):360-6 [6134747.001]
  • [Cites] Br J Obstet Gynaecol. 1983 Dec;90(12):1135-40 [6580910.001]
  • [Cites] Br J Obstet Gynaecol. 1984 Jul;91(7):673-80 [6589016.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • (PMID = 16140938.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U127684438; United Kingdom / Medical Research Council / / U.1276.00.004.00002.01/2(61014)
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / RNA, Messenger; 0 / Receptors, Prostaglandin; 0 / Vascular Endothelial Growth Factor A; 0 / prostaglandin F2alpha receptor; B7IN85G1HY / Dinoprost; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2694301; NLM/ UKMS2436
  •  go-up   go-down


90. Gümüs-Akay G, Unal AE, Elhan AH, Bayar S, Karadayt K, Sunguroglu A, Kadikiran A, Tükün A: DNA copy number changes in gastric adenocarcinomas: high resolution-comparative genomic hybridization study in Turkey. Arch Med Res; 2009 Oct;40(7):551-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA copy number changes in gastric adenocarcinomas: high resolution-comparative genomic hybridization study in Turkey.
  • The aim of this study was to identify the genomic imbalances of gains and/or losses in gastric adenocarcinomas from Turkish patients and to investigate their association with development and progression of this type of cancer.
  • METHODS: Forty three patients with gastric adenocarcinoma were enrolled in this study and genomic imbalances were analyzed by high-resolution-comparative genomic hybridization (HR-CGH).
  • RESULTS: In 36/43 cases (84%) of gastric adenocarcinomas, genomic imbalances have involved all chromosomes in various combinations.
  • CONCLUSIONS: A series of gains, losses and amplifications concerned with gastric adenocarcinoma identified in this study are presented in detail.
  • [MeSH-major] Adenocarcinoma / genetics. Comparative Genomic Hybridization / methods. DNA Copy Number Variations. Stomach Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 IMSS. Published by Elsevier Inc.
  • (PMID = 20082868.001).
  • [ISSN] 1873-5487
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


91. Janjigian YY, Park BJ, Kris MG, Miller VA, Riely GJ, Zheng J, Dycoco JP, Shen R, Azzoli CG: Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations. J Clin Oncol; 2009 May 20;27(15_suppl):7523

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor epidermal growth factor receptor (EGFR) mutations.
  • : 7523 Background: Patients with stage IV adenocarcinoma whose tumors harbor EGFR mutations have high rates of response (∼ 75%) and prolonged progression free survival after EGFR tyrosine kinase inhibitor (TKI) treatment.
  • Adjuvant cisplatin-based chemotherapy improves disease free survival (DFS) and overall survival (OS) in patients with resected stages IB-IIIA NSCLC.
  • To see if adjuvant treatment with EGFR TKI (gefitinib or erlotinib) improves DFS in patients with EGFR mutation NSCLC, we conducted a retrospective review of patients with resected lung adenocarcinoma harboring EGFR mutations, some of whom received EGFR TKIs postoperatively.
  • METHODS: With Institutional Review Board approval, clinical information was obtained on all patients with stage I-III lung adenocarcinoma harboring EGFR exon 19 or 21 mutations that underwent resection at MSKCC between May 2002 and August 2008.
  • RESULTS: We studied 150 patients (112 women, 38 men) with completely resected stage I-III lung adenocarcinoma whose resection specimens contained EGFR activating mutations in exon 19 or 21.
  • CONCLUSIONS: These data indicate that the adjuvant use of either gefitinib or erlotinib improves DFS in patients with completely resected stage I -III lung adenocarcinomas with mutations in EGFR exons 19 and 21.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963290.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Nakayama H, Yamada K, Saito H, Oshita F, Ito H, Kameda Y, Noda K: Sublobar resection for patients with peripheral small adenocarcinomas of the lung: surgical outcome is associated with features on computed tomographic imaging. Ann Thorac Surg; 2007 Nov;84(5):1675-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sublobar resection for patients with peripheral small adenocarcinomas of the lung: surgical outcome is associated with features on computed tomographic imaging.
  • BACKGROUND: Sublobar resection for peripheral small adenocarcinomas of the lung remains controversial.
  • METHODS: A total of 123 patients with adenocarcinoma of the lung underwent sublobar resection of clinical T1N0M0 tumors measuring 2 cm or less in diameter on high-resolution computed tomography.
  • CONCLUSIONS: Sublobar resection might be an acceptable procedure for the treatment of small air-containing type adenocarcinomas of the lung on preoperative high-resolution computed tomography.
  • [MeSH-major] Adenocarcinoma / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods. Radiography, Thoracic / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2008 Nov;86(5):1723-4; author reply 1724-5 [19049798.001]
  • (PMID = 17954084.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


93. Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Frontini L, Falconi M, Gallo C, Di Maio M: A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study. J Clin Oncol; 2009 May 20;27(15_suppl):4504

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas- GOIM/GISCAD/GOIRC) study.
  • : 4504 Background: Single-agent gemcitabine (G) remains standard treatment for advanced pancreatic adenocarcinoma (APC).
  • METHODS: Patients (pts) with locally advanced and/or metastatic pancreatic adenocarcinoma, age 18-75, Karnofsky Performance Status (KPS) ≥50, were randomized to receive G (arm A) or G+P (arm B).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Solis LM, Raso MG, Kalhor N, Behrens C, Wistuba II, Moran CA: Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases. Am J Clin Pathol; 2010 Jan;133(1):133-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary oncocytic adenocarcinomas of the lung: a clinicopathologic, immunohistochemical, and molecular biologic analysis of 16 cases.
  • Sixteen cases of primary oncocytic adenocarcinomas of the lung are reported.
  • Surgical staging disclosed 14 patients (88%) with stage I disease, 1 (6%) with stage II, and 1 (6%) with stage III.
  • These cases represent an unusual variant of pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology. Oxyphil Cells / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. DNA Mutational Analysis. DNA, Neoplasm / analysis. Fatal Outcome. Female. Humans. Lung / pathology. Lung / surgery. Male. Middle Aged. Mutation. Neoplasm Recurrence, Local. Neoplasm Staging. Proto-Oncogene Proteins / genetics. Receptor, Epidermal Growth Factor / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20023269.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


95. Sakao Y, Miyamoto H, Oh S, Takahashi N, Inagaki T, Miyasaka Y, Akaboshi T, Sakuraba M: The impact of cigarette smoking on prognosis in small adenocarcinomas of the lung: the association between histologic subtype and smoking status. J Thorac Oncol; 2008 Sep;3(9):958-62
MedlinePlus Health Information. consumer health - Smoking.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of cigarette smoking on prognosis in small adenocarcinomas of the lung: the association between histologic subtype and smoking status.
  • OBJECTIVE: In this retrospective study, we clarified the impact of smoking on prognosis and the association of clinicopathological factors, particularly histologic subtype, in patients with small adenocarcinoma of the lung.
  • METHODS: Between 1996 and December 2006, 121 patients presenting with adenocarcinomas that had a diameter </=2 cm were analyzed.
  • The clinicopathological records of the patients were examined for age, gender, nodal status (c-N and p-N), tumor size, serum carcinoembryonic antigen level, histologic subtype, and smoking history.
  • A histologic subtype was defined using a modified World Health Organization classification.
  • These subtypes are bronchioloalveolar carcinoma (BAC), adenocarcinoma with little or no BAC component (Non or min BAC), and mixed bronchioloalveolar carcinoma with other adenocarcinoma components.
  • Gender, serum carcinoembryonic antigen level, and histologic subtype were significantly associated with smoking status.
  • Histologic subtype (Non or min BAC) was the only significant prognostic factor in multivariate analyses.
  • The prevalence of smoking by histologic subtype was 27.3% for BAC, 43.2% for mixed bronchioloalveolar carcinoma, and 74.6% for Non or min BAC.
  • CONCLUSIONS: When adenocarcinomas were small (diameter </=2 cm) cigarette smoking and male gender were associated with Non or min BAC histologic subtypes, which are thought to have more aggressive biologic features resulting in poorer outcome compared with other subtypes.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology. Smoking / adverse effects
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758296.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Langer R, Feith M, Siewert JR, Wester HJ, Hoefler H: Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus. BMC Cancer; 2008;8:70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and clinical significance of glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus.
  • In this study we investigated the glucose regulated proteins GRP78 (BiP) and GRP94 (GP96) in a series of human esophageal adenocarcinomas to determine their implications in cancer progression and prognosis.
  • METHODS: Formalin-fixed, paraffin-embedded tissues of primary resected esophageal (Barrett) adenocarcinomas (n = 137) and corresponding normal tissue were investigated. mRNA-gene expression levels of GRP78 and GRP94 were determined by quantitative real-time RT-PCR after mRNA extraction.
  • CONCLUSION: We could demonstrate an association of GRP78 and GRP94 mRNA and protein expression with tumor stage and behaviour in esophageal adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Esophageal Neoplasms / genetics. HSP70 Heat-Shock Proteins / metabolism. Heat-Shock Proteins / metabolism. Membrane Proteins / metabolism. Molecular Chaperones / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Barrett Esophagus / complications. Disease Progression. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / analysis. Survival Analysis. Up-Regulation

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Oncol Rep. 2003 May;5(3):203-9 [12667417.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):645-54 [10922340.001]
  • [Cites] J Natl Cancer Inst. 2004 Sep 1;96(17):1300-10 [15339968.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 1994;4(1):1-18 [7987045.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Breast Cancer Res Treat. 1999 Mar;54(2):135-46 [10424404.001]
  • [Cites] World J Gastroenterol. 2005 Jan 21;11(3):429-32 [15637761.001]
  • [Cites] World J Gastroenterol. 2005 Feb 21;11(7):1056-9 [15742415.001]
  • [Cites] World J Gastroenterol. 2005 Apr 14;11(14):2072-9 [15810071.001]
  • [Cites] Cell Stress Chaperones. 2005 Spring;10(1):46-58 [15832947.001]
  • [Cites] Lung Cancer. 2005 Jul;49(1):55-62 [15949590.001]
  • [Cites] Cell Stress Chaperones. 2005 Summer;10(2):86-103 [16038406.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):419-29 [11159180.001]
  • [Cites] Trends Biochem Sci. 2001 Aug;26(8):504-10 [11504627.001]
  • [Cites] Surg Oncol. 2000 Jul;9(1):35-41 [11525305.001]
  • [Cites] Scand J Gastroenterol Suppl. 2001;(234):51-60 [11768562.001]
  • [Cites] Carcinogenesis. 2002 Jan;23(1):123-30 [11756233.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] FEBS Lett. 2007 Jul 31;581(19):3641-51 [17481612.001]
  • [Cites] Cancer Detect Prev. 2005;29(6):544-51 [16297569.001]
  • [Cites] N Engl J Med. 2005 Dec 29;353(26):2821-2; author reply 2821-2 [16382552.001]
  • [Cites] Clin Chim Acta. 2006 Feb;364(1-2):308-15 [16182273.001]
  • [Cites] Curr Mol Med. 2006 Feb;6(1):45-54 [16472112.001]
  • [Cites] Arch Biochem Biophys. 2006 Mar 15;447(2):155-66 [16497268.001]
  • [Cites] Electrophoresis. 2006 May;27(9):1840-52 [16645950.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7849-53 [16912156.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):741-4 [16861902.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5987-93 [17062670.001]
  • [Cites] Toxicology. 2007 Jan 18;229(3):253-61 [17161515.001]
  • [Cites] Cell Stress Chaperones. 2006 Winter;11(4):334-42 [17278882.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3496-9 [17440054.001]
  • [Cites] Recent Results Cancer Res. 2000;155:1-14 [10693234.001]
  • [Cites] Toxicol Appl Pharmacol. 2000 Mar 15;163(3):260-6 [10702365.001]
  • [Cites] Breast Cancer Res Treat. 2000 Jan;59(1):15-26 [10752676.001]
  • [Cites] J Cell Biochem. 2000 Apr;77(3):396-408 [10760948.001]
  • [Cites] Cell Stress Chaperones. 2004 Mar;9(1):76-87 [15270080.001]
  • (PMID = 18331622.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HSP70 Heat-Shock Proteins; 0 / Heat-Shock Proteins; 0 / Membrane Proteins; 0 / Molecular Chaperones; 0 / RNA, Messenger; 0 / glucose-regulated proteins; 0 / molecular chaperone GRP78
  • [Other-IDs] NLM/ PMC2270853
  •  go-up   go-down


97. Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA: Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol; 2008 Dec;89(3):278-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.
  • PATIENTS AND METHODS: A total of 51 study subjects with adenocarcinomas (Type I due to Siewert classification) of the esophagus underwent PET-CT scans before and after neoadjuvant chemoradiotherapy.
  • CONCLUSIONS: Tumor volume and TLG can be used to assess treatment response and survival in patients with esophageal adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Esophageal Neoplasms / pathology. Esophageal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Radiother Oncol. 2009 Aug;92(2):291 [19264369.001]
  • (PMID = 18701180.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


98. Vazquez M, Carter D, Brambilla E, Gazdar A, Noguchi M, Travis WD, Huang Y, Zhang L, Yip R, Yankelevitz DF, Henschke CI, International Early Lung Cancer Action Program Investigators: Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. Lung Cancer; 2009 May;64(2):148-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications.
  • PURPOSE: To study the histopathologic features of CT screen-detected Stage IA adenocarcinomas to determine whether survival differed by the proportion of bronchioloalveolar component (BAC) or by the presence of multiple lesions in node-negative patients.
  • METHODS: Five pathologists with expertise in pulmonary pathology examined 279 resected cases of adenocarcinomas, 30 mm or less in length diagnosed by CT screening for lung cancer.
  • The panel determined the consensus diagnosis for each case, identified additional cancers, and classified each case as solitary or non-solitary.
  • RESULTS: Of the cases of adenocarcinoma, 20 (7%) were BAC subtype, 246 (88%) mixed subtype and 13 (5%) adenocarcinoma-OTHER.
  • Kaplan-Meier 10-year survival rates were 100% for BAC and adeno-MIXED with 90-99% BAC cases, 95% for mixed with 1-90% BAC, 90% for those without a BAC component, and 75% for other cases.
  • Contrary to staging predictions, cases of non-solitary node-negative adenocarcinoma had the same excellent prognosis as solitary node-negative cases, suggesting that most of the small, node-negative multiple carcinomas probably represent multiple primaries rather than intrapulmonary metastasis.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2005 Jun;46(6):677-84 [15910599.001]
  • [Cites] Chest. 2005 Mar;127(3):768-77 [15764756.001]
  • [Cites] Am J Surg Pathol. 2006 May;30(5):606-13 [16699315.001]
  • [Cites] Ann Thorac Surg. 2006 Nov;82(5):1808-13; discussion 1813-4 [17062253.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1763-71 [17065637.001]
  • [Cites] Ann Thorac Surg. 2007 Jan;83(1):209-14 [17184664.001]
  • [Cites] Radiology. 2007 Feb;242(2):555-62 [17255425.001]
  • [Cites] Ann Thorac Surg. 2007 Feb;83(2):397-400 [17257959.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):233-41 [17192789.001]
  • [Cites] J Thorac Oncol. 2006 Nov;1(9 Suppl):S13-9 [17409995.001]
  • [Cites] Lung Cancer. 2007 May;56(2):193-9 [17239983.001]
  • [Cites] J Cardiovasc Surg (Torino). 2007 Jun;48(3):369-74 [17505443.001]
  • [Cites] Ann Thorac Surg. 2007 Sep;84(3):934-8; discussion 939 [17720402.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):763-8 [10701622.001]
  • [Cites] Lung Cancer. 2000 Sep;29(3):179-88 [10996420.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):153-9 [11443621.001]
  • [Cites] Ann Diagn Pathol. 2001 Dec;5(6):321-9 [11745069.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):9-14 [11891027.001]
  • [Cites] AJR Am J Roentgenol. 2002 May;178(5):1053-7 [11959700.001]
  • [Cites] Ann Thorac Surg. 2002 Oct;74(4):988-93; discussion 993-4 [12400733.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):101-9 [12502932.001]
  • [Cites] Lung Cancer. 2003 Feb;39(2):231-2 [12581579.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Mar;23(3):409-14 [12614815.001]
  • [Cites] Ann Thorac Surg. 2003 Jun;75(6):1745-51; discussion 1751 [12822610.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6D):4959-65 [14981952.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Mar;127(3):857-61 [15001917.001]
  • [Cites] Lung Cancer. 2004 Apr;44(1):43-51 [15013582.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jun;127(6):1574-8 [15173709.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1194-9 [15464469.001]
  • [Cites] J Thorac Cardiovasc Surg. 1970 Aug;60(2):275-90 [5451072.001]
  • [Cites] Cancer. 1976 Mar;37(3):1389-96 [1260659.001]
  • [Cites] Cancer. 1977 Apr;39(4):1647-55 [192433.001]
  • [Cites] Cancer. 1981 Mar 1;47(5 Suppl):1182-7 [6263446.001]
  • [Cites] Am Rev Respir Dis. 1984 Oct;130(4):549-54 [6091505.001]
  • [Cites] Am Rev Respir Dis. 1984 Oct;130(4):555-60 [6091506.001]
  • [Cites] Am Rev Respir Dis. 1984 Oct;130(4):561-5 [6091507.001]
  • [Cites] J Natl Cancer Inst. 1988 Nov 2;80(17):1404-7 [3172266.001]
  • [Cites] Cancer Res. 1995 Jan 1;55(1):135-40 [7805023.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):906-14 [9041152.001]
  • [Cites] Cancer. 1997 Apr 15;79(8):1521-6 [9118033.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Lancet. 1999 Jul 10;354(9173):99-105 [10408484.001]
  • [Cites] Histol Histopathol. 2006 Jun;21(6):627-32 [16528673.001]
  • (PMID = 18951650.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA070907-109001; United States / NCI NIH HHS / CA / R01 CA078905; United States / NCI NIH HHS / CA / R01-CA-78905; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / P50 CA070907-109001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Other-IDs] NLM/ NIHMS146973; NLM/ PMC2849638
  •  go-up   go-down


99. Pérez Escuredo J, Llorente JL, Melón S, de Oña M, García Martínez J, Alvarez Marcos C, Hermsen M: [Viral infection of herpes simplex, Epstein-Barr, varicela zoster, human papilloma, cytomegalovirus, or adenovirus are not related to sinonasal adenocarcinomas]. Acta Otorrinolaringol Esp; 2007 Aug-Sep;58(7):311-5
MedlinePlus Health Information. consumer health - Shingles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Viral infection of herpes simplex, Epstein-Barr, varicela zoster, human papilloma, cytomegalovirus, or adenovirus are not related to sinonasal adenocarcinomas].
  • [Transliterated title] Las infecciones por virus herpes simplex, Epstein-Barr, varicela zoster, papiloma humano, citomegalovirus o adenovirus no tienen relación con los adenocarcinomas nasosinusales.
  • However, until now sinonasal adenocarcinomas (ACN) have not been studied.
  • [MeSH-major] Adenocarcinoma / virology. Adenoviridae Infections / genetics. Epstein-Barr Virus Infections / genetics. Herpes Simplex / genetics. Herpes Zoster / genetics. Papillomavirus Infections / genetics. Paranasal Sinus Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Herpes Simplex.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17683698.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


100. Deng H, Makizumi R, Ravikumar TS, Dong H, Yang W, Yang WL: Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res; 2007 Mar 10;313(5):1033-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells.
  • In an analysis of human colon normal mucosa and tumors at different stages by immunohistochemistry, we observed that the intensity of BMP-4 staining in late-adenocarcinomas was stronger than that in normal mucosa and adenomas, while there was no difference in the staining of its receptors (BMPR-IA and BMPR-II) at all stages.
  • [MeSH-major] Adenocarcinoma / metabolism. Bone Morphogenetic Proteins / metabolism. Cell Movement. Colonic Neoplasms / metabolism. Intestinal Mucosa / metabolism. Liver Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17275810.001).
  • [ISSN] 0014-4827
  • [Journal-full-title] Experimental cell research
  • [ISO-abbreviation] Exp. Cell Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BMP4 protein, human; 0 / Bone Morphogenetic Protein 4; 0 / Bone Morphogenetic Proteins; 0 / RNA, Messenger; EC 2.7.11.30 / Bone Morphogenetic Protein Receptors, Type I; EC 2.7.11.30 / Bone Morphogenetic Protein Receptors, Type II; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down






Advertisement